Form 10-Q - Quarterly report [Sections 13 or 15(d)]

 

 

Table of Contents

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

 

FORM 10-Q

 

---

 

(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024.
	or
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ☐ to ☐

 

Commission File Number: 000-52684

 

---

 

Progressive Care Inc.

(Exact name of registrant as specified in its charter)

 

---

 

Delaware	32-0186005
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

 

400 Ansin Blvd., Suite A, Hallandale Beach, FL	33009
(Address of principal executive offices)	(Zip Code)

 

[phone]

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class		Trading Symbol		Name of each exchange on which registered
N/A		N/A		N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The number of shares of the registrant’s common stock outstanding as of May 10, 2024 was 6,240,731.

---

---

 

---

Table of Contents

 

 

PROGRESSIVE CARE INC. AND SUBSIDIARIES

INDEX

 

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	F-1
	Condensed Consolidated Balance Sheets	F-1
	Condensed Consolidated Statements of Operations	F-2
	Condensed Consolidated Statements of Stockholders’ Equity	F-3
	Condensed Consolidated Statements of Cash Flows	F-4
	Notes to the Condensed Consolidated Financial Statements	F-5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	9
Item 4.	Controls and Procedures	9
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	10
Item 1A.	Risk Factors	10
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities	10
Item 3.	Defaults Upon Senior Securities	10
Item 4.	Mine Safety Disclosures	10
Item 5.	Other Information	10
Item 6.	Exhibits	11
	Signatures	12

 

 

2

---

Table of Contents

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This quarterly report and other documents that we file with the Securities and Exchange Commission contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management’s assumptions. Statements that are not historical facts are forward-looking statements, including forward-looking information concerning pharmacy sales trends, prescription margins, number and location of new store openings, outcomes of litigation, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, acquisition synergies, regulatory approvals, and competitive strengths. Words such as “expect,” “outlook,” “forecast,” “would,” “could,” “should,” “project,” “intend,” “plan,” “continue,” “sustain,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “assume,” and variations of such words and similar expressions are often used to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those described in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on April 11, 2024 (“2023 Form 10-K”), this quarterly report on Form 10-Q for the three months ended March 31, 2024, and our other reports that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after the date they are made, whether as a result of new information, future events, changes in assumptions or otherwise.

 

3

---

Table of Contents

 

PART I - FINANCIAL INFORMATION

 

ITEM 1.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

PROGRESSIVE CARE INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except shares and par data)

(Unaudited)

	Successor
	March 31, 2024				December 31, 2023
Assets
Current Assets
Cash	$	5,544			$	7,895
Accounts receivable – trade, net		12,253				8,339
Receivables - other, net		2,068				1,846
Inventory, net		3,385				3,069
Prepaid expenses		185				334
Total Current Assets		23,435				21,483
Property and equipment, net		3,220				3,284
Other Assets
Goodwill		731				731
Intangible assets, net		13,706				14,398
Operating right-of-use assets, net		249				427
Finance right-of-use assets, net		18				22
Deposits		39				39
Total Other Assets		14,743				15,617
Total Assets	$	41,398			$	40,384
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued liabilities	$	13,555			$	12,158
Notes payable		144				145
Operating lease liabilities		159				170
Finance lease liabilities		20				18
Total Current Liabilities		13,878				12,491
Long-term Liabilities
Notes payable, net of current portion		1,081				1,110
Operating lease liabilities, net of current portion		182				214
Finance lease liabilities, net of current portion		—				5
Total Liabilities		15,141				13,820
Commitments and Contingencies		—				—
Stockholders’ Equity
Preferred Stock, Series A ($0.001 par value, 51 shares authorized and designated; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)		—				—
Preferred Stock, Series B ($0.0001 par value, 100,000 shares authorized and designated; 3,000 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)		—				—
Common stock ($0.0001 par value, 100,000,000 shares authorized; 6,240,731 and 6,222,781 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)		67				67
Additional paid-in capital		60,951				60,886
Accumulated deficit		(34,761	)			(34,389	)
Total Stockholders’ Equity		26,257				26,564
Total Liabilities and Stockholders’ Equity	$	41,398			$	40,384

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

F-1

---

Table of Contents

 

 

PROGRESSIVE CARE INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
Sales of products, net		$	11,255			$	9,794
Revenues from services			3,373				1,598
Revenues, net			14,628				11,392
Costs of products			10,560				8,196
Costs of services			63				49
Costs of revenue			10,623				8,245
Gross profit			4,005				3,147
Operating expenses
Salaries and wages			2,116				1,598
Professional fees			478				774
Depreciation and amortization			776				64
Selling, general, and administrative			900				697
Impairment loss			132				—
Total operating expenses			4,402				3,133
(Loss) income from operations			(397	)			14
Other income (expense):
Gain on sale or disposal of property and equipment			1				—
Interest income			40				6
Interest expense			(16	)			(150	)
Total other income (expense)			25				(144	)
Loss before income taxes			(372	)			(130	)
Provision for income taxes			-				—
Net loss attributable to common shareholders		$	(372	)		$	(130	)
Basic and diluted weighted average loss per common share		$	(0.06	)		$	(0.04	)
Weighted average number of common shares outstanding during the period – basic and diluted			6,240				3,356

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

F-2

---

Table of Contents

 

 

PROGRESSIVE CARE INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands)

(Unaudited)

 

		Preferred Stock, Series A								Preferred Stock, Series B								Common Stock								Additional								Total
		$0.001 Par Value								$0.0001 Par Value								$0.0001 Par Value								Paid-in				Accumulated				Stockholders’
		Shares				Amount				Shares				Amount				Shares				Amount				Capital				Deficit				Equity
Balance at December 31, 2023 (Successor)			—			$	—				3			$	—				6,223			$	67			$	60,886			$	(34,389	)		$	26,564
Stock-based compensation			—				—				—				—				18				—				65				—				65
Net loss for the three months ended March 31, 2024			—				—				—				—				—				—				—				(372	)			(372	)
Balance at March 31, 2024 (Successor)			—			$	—				3			$	—				6,241			$	67			$	60,951			$	(34,761	)		$	26,257

 

 

		Preferred Stock, Series A								Preferred Stock, Series B								Common Stock								Additional								Total
		$0.001 Par Value								$0.0001 Par Value								$0.0001 Par Value								Paid-in				Accumulated				Stockholders’
		Shares				Amount				Shares				Amount				Shares				Amount				Capital				Deficit				Equity
Balance December 31, 2022 (Predecessor)			—			$	—				3			$	—				3,347			$	67			$	22,525			$	(14,974	)		$	7,618
Stock-based compensation			—				—				—				—				11				—				50				—				50
Net loss for the three months ended March 31, 2023			—				—				—				—				—				—				—				(130	)			(130	)
Balance March 31, 2023 (Predecessor)			—			$	—				3			$	—				3,358			$	67			$	22,575			$	(15,104	)		$	7,538

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

F-3

---

Table of Contents

 

PROGRESSIVE CARE INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
Cash flows from operating activities:
Net loss		$	(372	)		$	(130	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation			79				44
Change in provision for doubtful accounts			2				9
Amortization of debt issuance costs and debt discounts			—				96
Stock-based compensation			65				60
Amortization of right-of-use assets - finance leases			5				8
Amortization of right-of-use assets - operating leases			44				36
Change in accrued interest on notes payable			—				34
Amortization of intangible assets			692				12
Gain on sale or disposal of property and equipment			(1	)			—
Impairment loss			132				—
Changes in operating assets and liabilities:
Accounts receivable			(4,138	)			(378	)
Grant receivable			—				(277	)
Inventory			(316	)			(550	)
Prepaid expenses			149				19
Deposits			—				(1	)
Accounts payable and accrued liabilities			1,423				1,885
Operating lease liabilities			(41	)			(40	)
Net cash (used in) provided by operating activities			(2,277	)			827
Cash flows from investing activities:
Purchase of property and equipment			(24	)			(17	)
Proceeds from sale or disposal of property and equipment			1				—
Net cash used in investing activities			(23	)			(17	)
Cash flows from financing activities:
Payments on notes payable			(46	)			(91	)
Payments on finance lease liabilities			(5	)			(10	)
Net cash used in financing activities			(51	)			(101	)
(Decrease) increase in cash			(2,351	)			709
Cash at beginning of period			7,895				6,743
Cash at end of period		$	5,544			$	7,452
Supplemental disclosures of cash flow information:
Cash paid for interest		$	16			$	19
Cash paid for income taxes		$	—			$	—

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

F-4

---

Table of Contents

 

PROGRESSIVE CARE INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

March 31, 2024

(Unaudited)

 

Unless the context requires otherwise, references to the “Company,” “we,” “us,” “our,” “our Company,” or “our business” refer to Progressive Care Inc. and its subsidiaries.

 

Note 1. Organization and Nature of Operations

 

Progressive Care Inc. (“Progressive”) was incorporated under the laws of the state of Delaware on October 31, 2006.

 

Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901”), Touchpoint RX, LLC doing business as Pharmco Rx 1002, LLC (“Pharmco 1002”), Family Physicians RX, Inc. doing business as PharmcoRx 1103 and PharmcoRx 1204 (“FPRX” or “Pharmco 1103” and “Pharmco 1204”) (pharmacy subsidiaries collectively referred to as “Pharmco”), and ClearMetrX Inc. (“ClearMetrX”) is a personalized healthcare services company that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers.

 

Pharmco 901 was formed on November 29, 2005 as a Florida Limited Liability Company and is a 100% owned subsidiary of Progressive. Pharmco 901 was acquired by Progressive on October 21, 2010. We currently deliver prescriptions to Florida’s diverse population and ship medications to patients in states where we hold non-resident pharmacy licenses as well. We currently hold Florida Community Pharmacy Permits at all Florida pharmacy locations and our Pharmco 901 location is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Illinois, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah. We are able to dispense to patients in the state of Massachusetts without a non-resident pharmacy license because Massachusetts does not require such a license for these activities.

 

Pharmco 1103 is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides Pharmco’s pharmacy services to Miami-Dade County, Broward County, the Orlando/Tampa corridor, and the Treasure Coast of Florida. Progressive acquired all the ownership interests in Pharmco 1103 in a purchase agreement entered into on June 1, 2019.

 

Pharmco 1002 is a pharmacy located in Palm Springs, Florida that provides Pharmco’s pharmacy services to Palm Beach, St. Lucie and Martin Counties, Florida. Progressive acquired all the ownership interests in Pharmco 1002 in a purchase agreement entered into on July 1, 2018.

 

ClearMetrX was formed on June 10, 2020 and provides third-party administration (“TPA”) services to 340B covered entities. ClearMetrX also provides data analytics and reporting services to support and improve care management for health care organizations.

 

RXMD Therapeutics was formed on October 1, 2019. RXMD Therapeutics has had no operating activity to date.

 

We have organized our operations into two reportable segments: Pharmacy Operations and TPA. See “Note 15. Reportable Segments.”

 

On June 30, 2023, NextPlat Corp (“NextPlat”), Charles M. Fernandez, Chairman and Chief Executive Officer of the Company, and Rodney Barreto, Vice-Chairman of the Company, entered into a voting agreement whereby at any annual or special shareholders meeting of the Company’s stockholders Messrs. Fernandez and Barreto agreed to vote all of the common stock shares that they own in the same manner that NextPlat votes its Common Stock and equivalents. On July 1, 2023, NextPlat and Messrs. Fernandez and Barreto exercised common stock purchase warrants and were issued 632,269, 211,470, and 130,571 common stock shares, respectively, by the Company. After the exercise of the common stock purchase warrants, NextPlat and Messrs. Fernandez and Barreto collectively owned 53% of the Company’s voting common stock. Collectively, the exercise of the common stock purchase warrants and the entry into the voting agreement constituted a change in control in Progressive Care. As a result of the change in control, NextPlat was deemed the accounting acquirer in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations and elected to apply push-down accounting. The application of push-down accounting created a new basis of accounting for all assets and liabilities based on their fair value at the date of acquisition, with few exceptions permissible under GAAP. As a result, the Company’s financial position, results of operations, and cash flows subsequent to the acquisition on July 1, 2023 have been segregated to indicate pre-acquisition and post-acquisition periods. The pre-acquisition period through June 30, 2023 is referred to as the “Predecessor Company”. The post-acquisition period, July 1, 2023 and forward, includes the impact of push-down accounting and is referred to as the “Successor Company”.

 

F- 5

---

Table of Contents

 

 

Note 2. Basis of Presentation and Principles of Consolidation

 

The accompanying Unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) on a basis consistent with reporting interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements.

 

Interim results are not necessarily indicative of the results that may be expected for the full year. Accordingly, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statements and notes thereto included in the 2023 Form 10-K. In the opinion of management, the Unaudited Condensed Consolidated Financial Statements contain all adjustments (consisting principally of normal recurring accruals) necessary for a fair presentation of the condensed consolidated balance sheets, statements of operations, statements of stockholders’ equity and statements of cash flows for such interim periods presented.

 

The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Certain 2023 financial information has been reclassified to conform to the 2024 presentation. Such reclassifications do not impact the Company’s previously reported financial position or net income (loss). On the Condensed Consolidated Statements of Operations, Revenues, net, Costs of revenue, and Operating expenses have been disaggregated for the three months ended March 31, 2023.

 

 

Note 3. Summary of Significant Accounting Policies

 

The significant accounting policies of the Company were described in Note 3 to the Audited Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to the Company’s significant accounting policies for the three months ended March 31, 2024. 

 

Cash

 

The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may exceed federally insured limits of $250,000. The Company had approximately $0.5 million that was uninsured as of  March 31, 2024. In July 2023, the Company entered into a deposit placement agreement for Insured Cash Sweep Services (“ICS”). This service is a secure and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000.

 

Concentrations

 

Suppliers:

 

The Company had significant concentrations with one vendor. The purchases from this significant vendor were 98% and 96% of total vendor purchases for the three months ended March 31, 2024 (Successor period) and the three months ended March 31, 2023 (Predecessor period), respectively.

 

F- 6

---

Table of Contents

 

Customers:

 

The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three most significant PBMs were as follows:

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
A			33	%			—
B			21	%			1	%
C			16	%			53	%

 

Direct and Indirect Remuneration (“DIR”) Fees

 

DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, for some PBMs, DIR fees were charged at the time of the settlement of a pharmacy claim. Other PBMs do not determine DIR fees at the claim settlement date, and therefore DIR fees are collected from pharmacies after claim settlement, often as clawbacks of reimbursements based on factors that vary from plan to plan. For example, two PBMs calculate DIR fees on a trimester basis and charge the Company for these fees as reductions of reimbursements paid to the Company two to three months after the end of the trimester (e.g., DIR fees for January – April 20xx claims were clawback by these PBMs in July – August 20xx). As of December 31, 2023, DIR fees that were not collected at the time of claim settlement, the Company recorded an accrued liability for estimated DIR fees that are expected to be collected by the PBMs by the end of the second quarter of 2024. The estimated liability for these fees is highly subjective and the actual amount collected may differ from the accrued liability. The uncertainty of management’s estimates is due to inadequate disclosure to the Company by the PBMs as to exactly how these fees are calculated either at the time the DIR fees are actually assessed and reported to the Company. The detail level of the disclosure of assessed DIR fees varies based on the information provided by the PBM. Effective January 1, 2024, all PBMs began charging DIR fees at the time of the settlement of a pharmacy claim.

 

Recently Adopted Accounting Standards

 

None.

 

Accounting Pronouncements Issued but not yet Adopted

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. ASU 2023-07 is required to be adopted for annual periods beginning after December 15, 2023, and interim period within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company will adopt the standard in its interim reporting beginning with Q1-2025, and the Company will adopt the standard in its annual reporting for the year ending December 31, 2024. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements but will enhance our current disclosures.

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740)—Improvements to Income Tax Disclosure” (“ASU 2023-09”), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. ASU 2023-09 is required to be adopted for annual periods beginning after December 15, 2024, with early adoption permitted. The Company will adopt this accounting standard update effective January 1, 2025. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements.

 

Subsequent Events

 

Merger Agreement

 

On April 12, 2024, the Company entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”) with NextPlat Corp, a Nevada corporation (“Parent”) and Progressive Care LLC, a Nevada limited liability company and a direct, wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Parent and the Company will enter into a business combination transaction pursuant to which the Company will merge with and into Merger Sub (the “Merger”) at the effective time of the Merger (the “Effective Time”), with Merger Sub being the surviving entity of the Merger.

 

The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three of the Company’s independent directors, each of whom does not have an interest in such transaction. The Merger Agreement was also approved by a special committee of Parent’s board of directors, which was affirmed by the entirety of Parent’s board of directors, as well as the sole member of Merger Sub.

 

Lock-Up Agreements

 

On April 9, 2024, the Company entered into lock-up agreements with each of its directors and executive officers (the “Company Lock-Up Agreements”). Additionally, separate lock-up agreements were established between the Company and the directors and executive officers of Parent (the “Parent Lock-Up Agreements”). Notably, individuals serving roles in both the Company and Parent, such as Charles M. Fernandez, Cecile Munnik, and Rodney Barreto, were covered by a single lock-up agreement with the Company relating to each of their shares in both the Company and Parent (the “Hybrid Lock-Up Agreements”, together with the Company Lock-Up Agreements and Parent Lock-Up Agreements, the “Lock-Up Agreements”). All Lock-Up Agreements prohibit the aforementioned stockholders from selling, transferring, acquiring or purchasing any of the securities of either the Company or Parent during the Interim Period. Notwithstanding the Lock-Up Agreements, the directors of the Company will continue to receive shares of the Company common stock payable to such director as compensation pursuant to the terms of his or her director services agreement.

 

F- 7

---

Table of Contents

  

 

Note 4. Fair Value Measurements

 

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

 

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

 

●

Cash, accounts receivable, and accounts payable and accrued liabilities: The amounts reported in the accompanying Condensed Consolidated Balance Sheets approximate fair value due to their short-term nature.

 

●

Notes payable and lease liabilities: The carrying amount of notes payable approximated fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing. The carrying value of lease liabilities approximated fair value due to the implicit rate in the lease in relation to the Company’s borrowing rate and the duration of the leases (Level 2 inputs).

 

Fair Value Measurement on a Nonrecurring Basis

 

Common Stock Purchase Warrants

 

As of March 31, 2024, the Company had common stock purchase warrants classified as Level 3 equity instruments. The fair value of the common stock purchase warrants on the date of issuance was approximately $4.6 million. The Company used the Monte Carlo simulation model for valuation of the common stock purchase warrants. Key inputs into the Monte Carlo simulation model were as follows at the valuation date: risk-free interest rate: 3.5%-3.7%; expected term: 3-5.6 years; expected volatility: 93%-102%; exercise price: $2.20. For additional information on the initial issuance and subsequent exercise of the common stock purchase warrants, see also “Note 13. Stockholder’s Equity, Common Stock and Common Stock Purchase Warrants.”

 

F- 8

---

Table of Contents

 

 

Note 5. Revenue

 

The following table disaggregates net revenues by categories (in thousands):

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
Sales of products, net
Prescription revenue, net of PBM fees		$	11,324			$	9,771
COVID-19 testing revenue			—				45
Subtotal			11,324				9,816
Revenues from services:
340B contract revenue			3,304				1,576
Revenues, net		$	14,628			$	11,392

 

 

Note 6. Earnings (Loss) per Share

 

Basic earnings per share is computed by dividing net (loss) income available to common shareholders by the weighted average number of common shares outstanding during the year, excluding the effects of any potentially dilutive securities. Diluted earnings per share gives effect to all potentially dilutive shares of common stock outstanding during the year including common stock purchase warrants and stock options, using the treasury stock method, and convertible debt, using the if converted method. Diluted earnings per share excludes all dilutive potential of shares of common stock if their effect is anti-dilutive.

 

The components of basic and diluted EPS were as follows (in thousands, except per share data). For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted loss per common share and basic loss per common share being equivalent.

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
Net loss attributable to common shareholders		$	(372	)		$	(130	)
Basic weighted average common shares outstanding			6,240				3,356
Potentially dilutive common shares			—				—
Diluted weighted average common shares outstanding			6,240				3,356
Basic weighted average loss per common share		$	(0.06	)		$	(0.04	)
Diluted weighted average loss per common share		$	(0.06	)		$	(0.04	)
Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share:
Common stock purchase warrants			102,468				60,152
Stock options			59,623				151,937
			162,091				212,089

 

F- 9

---

Table of Contents

 

 

Note 7. Accounts Receivable – Trade, net

 

Accounts receivable consisted of the following (in thousands):

		Successor
		March 31, 2024				December 31, 2023
Gross accounts receivable – trade		$	12,527			$	8,611
Less: allowance for credit losses			(274	)			(272	)
Accounts receivable – trade, net		$	12,253			$	8,339

 

The Successor Company increased the allowance for credit losses in the amount of approximately $2,000 for the three months ended March 31, 2024. The Predecessor Company increased the allowance of credit losses in the amount of approximately $9,000 for the three months ended March 31, 2023.

 

Accounts receivable – trade, net for the Predecessor Company as of January 1, 2023 and  March 31, 2023 were approximately $3.4 million and $4.3 million, respectively.

 

Note 8. Receivables – Other, net

 

Receivables – Other, net consisted of the following (in thousands):

		Successor
		March 31, 2024				December 31, 2023
Performance bonuses		$	1,859			$	1,602
Customers			179				192
Other			30				52
		$	2,068			$	1,846

 

Performance bonuses, paid annually by PBMs, are estimated based on historical pharmacy performance and prior payments received. Other receivables are loans to employees.

 

Note 9. Property and Equipment, net

 

Property and equipment, net consisted of the following (in thousands):

						Successor
		Estimated Useful Life				March 31, 2024				December 31, 2023
Building		40 years				$	2,116			$	2,116
Vehicles		3 - 5 years					585				595
Furniture and equipment		5 years					388				388
Land			---				184				184
Leasehold improvements and fixtures		Lesser of estimated useful life or life of lease					119				76
Computer equipment		3 years					39				39
Construction in progress			---				—				22
Total							3,431				3,420
Less: accumulated depreciation							(211	)			(136	)
Property and equipment, net						$	3,220			$	3,284

 

Depreciation expense for the Successor Company was approximately $79,000 for the three months ended March 31, 2024. Depreciation expense for the Predecessor Company was approximately $44,000 for the three months ended March 31, 2023.

 

F- 10

---

Table of Contents

 

 

Note 10. Goodwill and Intangible Assets

 

Goodwill

 

Goodwill was approximately $0.7 million as of March 31, 2024 and December 31, 2023 (Successor periods), and was allocated to the TPA reporting segment. There were no changes in the carrying amount of goodwill during the three months ended March 31, 2024.

 

Intangible Assets

 

Intangible assets consisted of the following (in thousands):

 

		Successor
		March 31, 2024											December 31, 2023
		Gross amount			Accumulated amortization				Net Amount				Gross amount			Accumulated amortization				Net Amount
Pharmacy records		$	8,130		$	(1,219	)		$	6,911			$	8,130		$	(807	)		$	7,323
Tradenames			4,700			(353	)			4,347				4,700			(224	)			4,476
Developed technology			2,880			(432	)			2,448				2,880			(281	)			2,599
Total intangible assets		$	15,710		$	(2,004	)		$	13,706			$	15,710		$	(1,312	)		$	14,398

 

Amortization of intangible assets for the Successor Company was approximately $0.7 million for the three months ended March 31, 2024. Amortization of intangible assets for the Predecessor Company was approximately $12,000 for the three months ended March 31, 2023.

 

The following table represents the total estimated future amortization of intangible assets for the five succeeding years and thereafter as of March 31, 2024 (in thousands):

 

		Successor
Year		Amount
2024 (remaining nine months)		$	2,004
2025			2,672
2026			2,672
2027			2,672
2028			1,571
Thereafter			2,115
Total		$	13,706

 

 

F- 11

---

Table of Contents

 

Note 11. Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following (in thousands):

 

		Successor
		March 31, 2024				December 31, 2023
Accounts payable – trade		$	12,752			$	11,256
Accrued payroll and payroll taxes			356				167
Accrued PBM fees			366				571
Other accrued liabilities			81				164
Total		$	13,555			$	12,158

 

 

Note 12. Notes Payable

 

Notes payable consisted of the following (in thousands):

 

		Successor
		March 31, 2024				December 31, 2023
A. Mortgage note payable - commercial bank - collateralized		$	1,118			$	1,140
B. Note payable - uncollateralized			25				25
C. Notes payable - collateralized			82				90
Subtotal			1,225				1,255
Less: current portion of notes payable			(144	)			(145	)
Long-term portion of notes payable		$	1,081			$	1,110

 

The corresponding notes payable above are more fully discussed below:

 

(A) Mortgage Note Payable – collateralized

 

In 2018, Pharmco 901 closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $1,530,000. The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on December 14, 2028 and is subject to a prepayment penalty. Principal and interest will be repaid through 119 regular payments of $11,901 that began in January 2019, with the final payment of all principal and accrued interest not yet paid on December 14, 2028. Note repayment is guaranteed by Progressive Care Inc.

 

(B) Note Payable – Uncollateralized

 

As of March 31, 2024 and December 31, 2023, the uncollateralized note payable represents a noninterest-bearing loan that is due on demand from an investor.

 

(C) Notes Payable – Collateralized

 

In April 2021, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $30,000. During September 2021, pharmacy equipment was returned since the installation was cancelled and the note was amended. The amended promissory note payable requires 46 monthly payments of $331, including interest at 6.9%. The balance outstanding as of March 31, 2024 and December 31, 2023 on the note payable was approximately $5,000 and $6,000, respectively.

 

F- 12

---

Table of Contents

 

In July 2022, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $90,000. The terms of the promissory note payable require 60 monthly payments of $1,859, including interest at 8.78% starting January 2023. The balance outstanding on the note payable was approximately $70,000 and $74,000 as of March 31, 2024 and December 31, 2023, respectively. The promissory note is secured by equipment with a net book value of approximately $68,000 and $71,000 as of March 31, 2024 and December 31, 2023, respectively.

 

In September 2022, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase a vehicle in the amount of approximately $25,000. The terms of the promissory note payable require 24 monthly payments of $1,143, including interest at 8.29% starting October 2022. The balance outstanding on the note payable was approximately $7,000 and $10,000 as of March 31, 2024 and December 31, 2023, respectively. The promissory note is secured by the vehicle with a net book value of approximately $17,000 and $18,000 as of March 31, 2024 and December 31, 2023, respectively.

 

Principal outstanding as of March 31, 2024, is expected to be repayable as follows (in thousands):

 

		Successor
Year		Amount
2024 (remaining nine months)		$	115
2025			114
2026			119
2027			124
2028			753
Total		$	1,225

 

Interest expense on these notes payable for the Successor Company was approximately $16,000 for the three months ended March 31, 2024. Interest expense on notes payable, exclusive of debt discount and debt issue cost amortization, for the Predecessor Company was approximately $51,000 for the three months ended March 31, 2023.

 

Note 13. Stockholders’ Equity

 

Preferred Stock

 

The Company has 10,000,000 shares of preferred stock authorized. As of March 31, 2024 and December 31, 2023, 51 shares are designated as Series A Preferred Stock, par value $0.001 per share, 100,000 shares are designated as Series B Preferred Stock, par value $0.0001 per share, and 9,899,949 shares are undesignated preferred shares, par value $0.0001 per share.

 

Series A Preferred Stock - Predecessor Company

 

The Series A preferred stock is a non-dividend producing instrument that ranks superior to the Company’s common stock. Each one (1) share of the Series A Preferred Stock shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding common stock and Preferred Stock eligible to vote at the time of the respective vote (the “Numerator”), divided by (y) 0.49, minus (z) the Numerator.

 

With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Series A Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.

 

In July 2014, the board of directors approved the issuance of 51 shares of the Company’s Series A Preferred Stock to a certain employee of the Company, which is equal to 50.99% of the total voting power of all issued and outstanding voting capital of the Company in satisfaction of $20,000 in past due debt. In October 2020, the preferred shares were transferred to a trust whose beneficiary is related to the employee. In August 2022, the Company entered into a Share Exchange Agreement with the trust in which the 51 shares of the Company’s Series A Preferred Stock were acquired from the trust and cancelled in exchange for the issuance of 127,564 shares of the Company’s common stock.

 

F- 13

---

Table of Contents

 

Series B Convertible Preferred Stock - Predecessor Company

 

On August 30, 2022, the  Company entered into a Securities Purchase Agreement with NextPlat wherein the Company sold 3,000 units, generating gross proceeds of $6.0 million. Each unit is made up of one share of Series B Convertible Preferred Stock, $0.0001 par value, and Investor Warrants. Each warrant entitles the holder to purchase one share of Series B Convertible Preferred Stock at an exercise price of $2,000. The Investor Warrants may also be exercised, in whole or in part, by means of a cashless exercise. The Series B Convertible Preferred Stock has a stated value of $2,000 per share and each Preferred Stock share has the equivalent voting rights of 500 common stock shares. Each share of Series B Convertible Preferred Stock is convertible at any time at the option of the holder into shares of the Company’s common stock determined by dividing the stated value by the conversion price which is $4.00. The Company incurred offering costs associated with the transaction of approximately $1.0 million.

 

The Series B Convertible Preferred Stock ranks senior to our common stock as to distribution of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The shares of Series B Convertible Preferred Stock shall have a liquidation preference to all other classes of stock of the Company in the amount of $2,000 per share. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series B Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company (i) $2,000 per share plus (ii) the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock which amounts shall be paid pari passu with all holders of common stock.

 

With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws. 

 

Common Stock and Common Stock Purchase Warrants

 

On May 5, 2023, the Predecessor Company entered into a Securities Purchase Agreement with NextPlat, pursuant to which NextPlat agreed to purchase 455,000 newly issued units of securities from the Predecessor Company (the “Units”) at a price per Unit of $2.20 for an aggregate purchase price of $1.0 million (the “Unit Purchase”). Each Unit consists of one share of common stock, par value $0.0001 per share, of Progressive Care (“Common Stock”) and one common stock purchase warrant to purchase a share of Common Stock (the “PIPE Warrants”). The PIPE Warrants have a three-year term and will be immediately exercisable. Each PIPE Warrant is exercisable at $2.20 per share of Common Stock. The Predecessor Company received cash proceeds of $880,000, net of placement agent commission of $70,000 and legal fees of $50,000. The Company accounted for the PIPE Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the PIPE Warrants was approximately $1.0 million. On July 1, 2023, NextPlat exercised the PIPE Warrants on a cashless basis and was issued 230,056 common stock shares.

 

Also on May 5, 2023, the Predecessor Company entered into a Debt Conversion Agreement (“DCA”) with NextPlat and the other Holders of that certain Amended and Restated Secured Convertible Promissory Note, dated as of September 2, 2022, made by the Predecessor Company in the original face amount of approximately $2.8 million (the “Note”). Pursuant to the DCA, NextPlat and the other Holders agreed to modify and convert the total approximately $2.9 million of outstanding principal and accrued and unpaid interest to common stock at a conversion price of $2.20 per share (the “Debt Conversion”). Of the total 1,312,379 shares of common stock issued upon conversion of the Note pursuant to the DCA, NextPlat received 570,599 shares, Charles M. Fernandez, the Company’s Chairman and Chief Executive Officer, received 228,240 shares, and Rodney Barreto, the Company’s Vice-Chairman of the Board of Directors, received 228,240 shares. In addition, each of the Holders also received a common stock purchase warrant to purchase one share of common stock for each share of common stock they received upon conversion of the Note (the “Conversion Warrants”). The Conversion Warrants have a three-year term and will be immediately exercisable. Each Conversion Warrant is exercisable at $2.20 per share of Common Stock. The Company accounted for the Conversion Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Conversion Warrants was approximately $2.7 million. On July 1, 2023, NextPlat and Messrs. Fernandez and Barreto exercised the Conversion Warrants. NextPlat exercised 230,000 Conversion Warrants on a cash basis and paid consideration in the amount of $506,000 and was issued 230,000 common stock shares. NextPlat exercised the remaining 340,599 Conversion Warrants on a cashless basis and was issued 172,213 common stock shares. Messrs. Fernandez and Barreto exercised the Conversion Warrants on a cashless basis and were each issued 115,402 common stock shares. As of March 31, 2024, the fair value of the remaining Conversion Warrants was approximately $0.6 million.

 

F- 14

---

Table of Contents

 

At the same time as the SPA and DCA, the Predecessor Company and NextPlat entered into the Debenture Purchase Agreement. Under the Debenture Purchase Agreement, the Predecessor Company agreed to issue, and NextPlat agreed to purchase, from time to time during the three-year term of the Debenture Purchase Agreement, up to an aggregate of $10.0 million of Debentures to NextPlat. Pursuant to the Amendment, NextPlat and the Predecessor Company agreed to amend the Debenture Purchase Agreement and the form of Debenture to have a conversion price of $2.20 per share. As of March 31, 2024, no Debentures have been purchased by NextPlat under the Debenture Purchase Agreement.

 

Dawson James Securities, Inc. (the “Placement Agent”) served as placement agent for the Unit Purchase. In consideration for the Placement Agent’s services, the Predecessor Company issued to the Placement Agent and its affiliates warrants to purchase 91,000 shares of Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants have a five-year term and will be exercisable in December 2023. Each Placement Agent Warrant is exercisable at $2.20 per share of Common Stock. The Company accounted for the Placement Agent Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Placement Agent Warrants was approximately $0.2 million.

 

In addition, the Predecessor Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the “Inducement Warrants”). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three-year term and will be immediately exercisable. Each Inducement Warrant is exercisable at $2.20 per share of Common Stock. The Company accounted for the Inducement Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Inducement Warrants was approximately $0.7 million. On July 1, 2023, Messrs. Fernandez and Barreto exercised the Inducement Warrants on a cashless basis and were issued 96,068 and 15,169 common stock shares, respectively. As of March 31, 2024, the fair value of the remaining Inducement Warrants was approximately $0.2 million.

 

Note 14. Stock-Based Compensation

 

Stock-based compensation is recorded in selling, general, and administrative expenses in the Unaudited Condensed Consolidated Statement of Operations. The Successor Company recorded total stock-based compensation expense of approximately $65,000 for the three months ended March 31, 2024. The Predecessor Company recorded total stock-based compensation expense of approximately $60,000 for the three months ended March 31, 2023. There were no income tax benefits recognized from stock-based compensation during the respective periods due to cumulative losses and valuation allowances.

 

Note 15. Reportable Segments

 

The Company has two reportable segments: (i) Pharmacy Operations, which provides prescription pharmaceuticals, compounded medications, tele-pharmacy services, COVID-19 related diagnostics and vaccinations, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, and contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program and (ii) Third-Party Administration, which provides data management and reporting services to support health care organizations. Operating expenses are reflected in the segment in which the costs are incurred.

 

Corporate includes certain assets and expenses related to corporate functions that are not specifically attributable to an individual reportable segment, such as legal, public company expenses, tax compliance and senior executive staff. 

 

The Company evaluates the performance of each of the segments based on income (loss) from operations. While the Company believes there are synergies between the two business segments, the segments are managed separately because each requires different business strategies.

 

The accounting policies used to determine the results of the operating segments are the same as those utilized for the Consolidated Financial Statements as a whole. There are no inter-segment sales or transfers.

 

The following tables present a summary of net income (loss) of the reportable segments (in thousands):

 

F- 15

---

Table of Contents

 

		Successor
		Three Months Ended March 31, 2024
		Pharmacy Operations				Third-Party Administration				Corporate				Total Consolidated
Sales of products, net		$	11,255			$	—			$	—			$	11,255
Revenues from services			2,840				533				—				3,373
Revenues, net			14,095				533				—				14,628
Costs of products			10,560				—				—				10,560
Costs of services			—				63				—				63
Costs of revenue			10,560				63				—				10,623
Gross profit			3,535				470				—				4,005
Operating expenses:
Salaries and wages			1,901				33				182				2,116
Professional fees			4				81				393				478
Depreciation and amortization			615				156				5				776
Selling, general, and administrative			770				7				123				900
Impairment loss (1)			132				—				—				132
Total operating expenses			3,422				277				703				4,402
Income (loss) from operations			113				193				(703	)			(397	)
Other (expense) income			(14	)			—				39				25
Income (loss) before income taxes			99				193				(664	)			(372	)
Provision for income taxes			—				—				—				—
Net income (loss)		$	99			$	193			$	(664	)		$	(372	)

---

(1) Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

 

F- 16

---

Table of Contents

 

		Predecessor
		Three Months Ended March 31, 2023
		Pharmacy Operations				Third-Party Administration				Corporate				Total Consolidated
Sales of products, net		$	9,794			$	—			$	—			$	9,794
Revenues from services			1,081				517				—				1,598
Revenues, net			10,875				517				—				11,392
Costs of products			8,196				—				—				8,196
Costs of services			—				49				—				49
Costs of revenue			8,196				49				—				8,245
Gross profit			2,679				468				—				3,147
Operating expenses:
Salaries and wages			1,445				33				120				1,598
Professional fees			383				96				295				774
Depreciation and amortization			60				4				—				64
Selling, general, and administrative			588				4				105				697
Total operating expenses			2,476				137				520				3,133
Income (loss) from operations			203				331				(520	)			14
Other expense			(13	)			—				(132	)			(144	)
Income (loss) before income taxes			190				331				(652	)			(130	)
Provision for income taxes			—				—				—				—
Net income (loss)		$	190			$	331			$	(652	)		$	(130	)

 

F- 17

---

Table of Contents

 

		Pharmacy Operations				Third-Party Administration				Corporate				Eliminations (1)				Total Consolidated
Total Assets as of March 31, 2024 (Successor)		$	39,439			$	4,733			$	—			$	(2,774	)		$	41,398
Total Assets as of December 31, 2023 (Successor)		$	38,516			$	4,573			$	69			$	(2,774	)		$	40,384

---

(1) Eliminations consist of investments in subsidiaries between the Pharmacy Operations segment and Corporate.

 

Capital expenditures for the Pharmacy Operations reporting segment were approximately $0.1 million for the three months ended March 31, 2024 (Successor period). Capital expenditures for the Pharmacy Operations reporting segment were approximately $17,000 for the three months ended March 31, 2023 (Predecessor period). There were no capital expenditures for the TPA reporting segment during the three months ended March 31, 2024 (Successor period) and the three months ended March 31, 2023 (Predecessor period).

 

 

Note 16. Related Party Transactions

 

Successor Company

 

During the three months ended March 31, 2024, the Successor Company paid $60,000 to NextPlat as management fees in accordance with the amended Management Services Agreement (the “Management Agreement”) dated May 1, 2023.

 

Predecessor Company

 

On February 1, 2023, the Predecessor Company entered into the Management Agreement with NextPlat Corp to provide certain management and administrative services to the Predecessor Company for $25,000 per month fee. On May 1, 2023, the Management Agreement was amended to update the fee to $20,000 per month. During the three months ended March 31, 2023, the Predecessor Company paid $50,000 to NextPlat as management fees.

 

F- 18

---

Table of Contents

 

 

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and notes thereto included under Part I, Item I of this Quarterly Report on Form 10-Q. In addition, reference should be made to our audited Consolidated Financial Statements and notes thereto and related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2023 Form 10-K. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs, including potential impacts on our business, results of operations and financial condition. Our actual results may differ materially from those contained in or implied by any forward-looking statements. The financial information included in this discussion and in our consolidated financial statements may not be indicative of our consolidated financial position, operating results, changes in equity and cash flows in the future. See “Special Note Regarding Forward-Looking Statements” included earlier in this report.

 

Note on Financial Presentation

 

In connection with the change in control on July 1, 2023, the application of push-down accounting created a new basis of accounting for all assets and liabilities based on their fair value at the date of acquisition. As a result, our financial position, results of operations, and cash flows subsequent to the acquisition on July 1, 2023 have been segregated to indicate pre-acquisition and post-acquisition periods. The pre-acquisition period through June 30, 2023 is referred to as the “Predecessor”. The post-acquisition period, July 1, 2023 and forward, includes the impact of push-down accounting and is referred to as the “Successor”.

 

The information contained below should be read in conjunction with our historical condensed consolidated financial statements and the related notes.

 

Overview

 

Progressive Care Inc. was incorporated under the laws of the state of Delaware on October 31, 2006 under the name Progressive Training, Inc. We changed our name to Progressive Care Inc. in connection with a merger with Progressive Care Inc. on November 23, 2010. We are a personalized healthcare services and technology company which provides prescription pharmaceutical and risk and data management services to healthcare organizations and providers.

 

We currently own and operate five pharmacies, which generate most of our pharmacy revenues, which is derived from dispensing medications to our patients. We also provide patient health risk reviews and free same-day delivery.

 

We provide TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management. We are focused on improving the lives of patients with complex chronic diseases through a patient and provider engagement and our partnerships with payors, pharmaceutical manufacturers, and distributors. We offer a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

 

Pharmco provides contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program. Under the terms of these agreements, we act as a pass-through for reimbursements on prescription claims adjudicated on behalf of the 340B covered entities in exchange for a dispensing fee per prescription. These fees vary by the covered entity and the level of service provided by us.

 

4

---

Table of Contents

 

Our focus is on complex chronic diseases that generally require multiyear or lifelong therapy, which drives recurring revenue and sustainable growth. Our pharmacy services revenue growth is from expanding our services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers due to our focus on higher patient engagement, benefit of free delivery to the patient, and clinical expertise. We also expanded revenue growth through the signing of new contract pharmacy service and data management contracts with 340B covered entities.

 

ClearMetrX includes data management and TPA services for 340B covered entities, pharmacy analytics, and programs to manage HEDIS Quality Measures including Medication Adherence. These offerings cater to the need for frontline providers to understand best practices, patient behaviors, care management processes, and the financial mechanisms behind these decisions. We provide data access, and actionable insights that providers and support organizations can use to improve their practice and patient care. The Company’s TPA services include management of wholesale accounts, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

 

Our 340MetrX platform provides 340B covered entities with data insights to effectively operate and maximize the benefits of the 340B program. The platform allows program administrators to manage, in real time, data related to revenue, virtual inventory, drug replenishment and reconciliation, detailed prescription history analysis, customized ordering data with major wholesalers, patient information, drug prescribing trends, and customized financial breakdowns. The 340MetrX software enhances services currently provided to 340B covered entities by complementing in-house 340B experts with a reporting platform aiming to maximize the limited resources in the 340B space through identification and validation of claims. 340MetrX allows our data analytics processes to be more efficient, giving our team the ability to seamlessly manage data for a much greater number of 340B covered entities in Florida, with potential to be scaled nationwide.

 

Critical Accounting Policies and Estimates

 

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation included in our 2023 Form 10-K. The most recently adopted accounting pronouncements and accounting pronouncements to be adopted by the Company are described in Note 3 in the Notes to our Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

 

Results of Operations

 

Three months ended March 31, 2024 compared to the three months ended March 31, 2023

 

The following table summarizes our results of operations (in thousands):

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023				$ Change			% Change
Total revenues, net		$	14,628			$	11,392			$	3,236			28	%
Total cost of revenue			10,623				8,245				2,378			29	%
Total gross profit			4,005				3,147				858			27	%
Operating expenses			4,402				3,133				1,269			41	%
(Loss) income from operations			(397	)			14				(411	)		(2936	)%
Other income (expense)			25				(144	)			169			(117	)%
Loss before income taxes			(372	)			(130	)			(242	)		186	%
Provision for income taxes			—				—				—			—
Net loss attributable to common shareholders		$	(372	)		$	(130	)		$	(242	)		186	%

 

We recognized overall revenue from operations of approximately $14.6 million and $11.4 million during the three months ended March 31, 2024 and 2023, respectively, an overall increase of approximately $3.2 million, or 28%. The increase in revenue was primarily attributable to an increase in prescription revenue, net of PBM fees of approximately $1.6 million and an increase in 340B contract revenue of approximately $1.7 million, which was offset by a decrease in COVID-19 testing revenue of approximately $45,000, when compared to the prior year period.

5

---

Table of Contents

 

Overall gross profit margins decreased from 28% for the three months ended March 31, 2023 to 27% for the three months ended March 31, 2024. The increase in gross profit of approximately $0.9 million was primarily attributable to (i) a favorable increase in reimbursement rates per prescription of approximately $1.0 million, which was offset by the unfavorable increase in drug cost per prescription of approximately $1.9 million; (ii) a favorable increase in pharmacy prescription volume of approximately $0.1 million; and (iii) a favorable increase in 340B contract revenue of approximately $1.7 million. The unfavorable significant increase in drug cost per prescription, negatively impacted our overall gross profit margin.

 

Loss from operations was approximately $0.4 million for the three months ended March 31, 2024, compared to an income from operations of approximately $14,000 for the three months ended March 31, 2023, a decrease of approximately $0.4 million primarily attributable to the increase in operating expenses, partially offset by the increase in gross profits. See below for further explanation relating to the increase in operating expenses.

 

Revenue

 

Our revenues were as follows (in thousands):

 

		Successor						Predecessor
		Three Months Ended March 31, 2024						Three Months Ended March 31, 2023
		Dollars			% of Revenue			Dollars			% of Revenue			$ Change			% Change
Sales of products, net
Prescription revenue, net of PBM fees		$	11,324		77	%		$	9,771		86	%		$	1,553			16	%
COVID-19 testing revenue			—		—	%			45		—	%			(45	)		(100	)%
Subtotal			11,324		77	%			9,816		86	%			1,508			15	%
Revenues from services:
340B contract revenue			3,304		23	%			1,576		14	%			1,728			110	%
Revenues, net		$	14,628		100	%		$	11,392		100	%		$	3,236			28	%

 

We have filled approximately 134,000 and 120,000 prescriptions during the three months ended March 31, 2024 and 2023, respectively, resulting in a favorable impact on prescription revenue of approximately $0.6 million. Revenue per prescription filled was also favorably impacted by the increase of reimbursement rates per prescription of approximately $1.0 million, when compared to the prior year period.

 

Dispensing fees and TPA revenue earned on our 340B contracts for the three months ended March 31, 2024 and 2023 were approximately $3.3 million and $1.6 million, respectively, an increase of approximately $1.7 million. The increase in 340B contract revenue was attributable to an increase in our existing 340B contracts of approximately $0.8 million and an increase in new 340B contract revenue of approximately $0.9 million.

 

Operating Expenses

 

Our operating expenses increased by approximately $1.3 million, or 41%, for the three months ended March 31, 2024, as compared to the prior year period. The increase was primarily attributable to the following:

 

●	approximately $0.7 million increase in the amortization of newly identifiable intangible assets as a result of the push-down accounting;
●	approximately $0.5 million increase in salaries and wages due to a combination of performance-based salary adjustments and additional headcount, net of attrition due to normal employee turnover;
●	approximately $0.1 million of impairment loss related to the write-down of a right-of-use asset; and
●	approximately $0.1 million increase in computer expenses.

 

During the three months ended March 31, 2024, the right-of-use asset impairment was a result of taking the leased equipment out of service and not returning to service in the future.

 

Other Income (Expense)

 

Other income (expense) increased by approximately $0.2 million for the three months ended March 31, 2024, as compared to the prior year period, primarily attributable to the decrease in interest expense as a result of the decrease in notes payable.

 

Net Loss

 

We had a net loss of approximately $0.4 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively. The increase in net loss was primarily attributable to the decrease in operating income.

 

6

---

Table of Contents

 

Non-GAAP Financial Measures

 

We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, stock-based compensation, and certain other items that we do not consider indicative of our ongoing operating performance (which items are itemized below). Adjusted EBITDA is a non-GAAP financial measure.

 

We consider Adjusted EBITDA to be a supplemental measure of our operating performance. We present Adjusted EBITDA because it is used by our Board of Directors and management to evaluate our operating performance. It is also used as a factor in determining incentive compensation, for budgetary planning and forecasting overall financial and operational expectations, for identifying underlying trends, and for evaluating the effectiveness of our business strategies. Further, we believe it assists us, as well as investors, in comparing performance from period to period on a consistent basis. Adjusted EBITDA is not in accordance with, or an alternative to, measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles.

 

As a non-GAAP measure, Adjusted EBITDA has limitations in that it does not reflect all the amounts associated with our results of operations as determined in accordance with U.S. GAAP and therefore you should not consider Adjusted EBITDA in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP. You should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in the presentation, and we do not infer that our future results will be unaffected by unusual or non-recurring items. Adjusted EBITDA does not include:

 

●	depreciation expense from property and equipment or amortization expense from intangible assets (and although they are non-cash charges, the assets being depreciated/amortized will often have to be replaced in the future);
●	interest expense on our debt and capital leases or interest income we earn on cash;
●	the amounts we paid in taxes or other components of our tax provision (which reduces cash available to us);
●	change in fair value of derivatives;
●	certain expenses associated with our acquisition activities; or
●	the impact of stock-based compensation or other matters we do not consider to be indicative of our ongoing operations.

 

Further, other companies in our industry may calculate Adjusted EBITDA differently than we do and these calculations may not be comparable to our Adjusted EBITDA metric. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss attributable to us and our financial results presented in accordance with U.S. GAAP.

 

The table below presents a reconciliation of the most directly comparable U.S. GAAP measure, net loss attributable to us, to Adjusted EBITDA for the periods indicated below (in thousands):

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
Net loss		$	(372	)		$	(130	)
Interest expense			16				150
Depreciation and amortization expense			776				64
Consolidated adjusted EBITDA		$	420			$	84

 

7

---

Table of Contents

 

Liquidity and Capital Resources

 

Cash Flows

 

The following table summarizes our cash flows:

 

		Successor				Predecessor
		Three Months Ended March 31, 2024				Three Months Ended March 31, 2023
Net change in cash from:
Operating activities		$	(2,277	)		$	827
Investing activities			(23	)			(17	)
Financing activities			(51	)			(101	)
Change in cash			(2,351	)			709
Cash at end of period		$	5,544			$	7,452

 

Net cash used in operating activities totaled approximately $2.3 million for the three months ended March 31, 2024, compared to net cash provided by operating activities of approximately $0.8 million for the same period in 2023. Operational cash flows decreased primarily due to the timing difference of accounts payable to our 340B covered entities and receiving the reimbursements related to those 340B claims. The payments that were due to the covered entities at the end of the first quarter of 2024 were paid on the last business day of the quarter, however the collections of reimbursements for the 340B claims were not received until the first business day of the second quarter of 2024.

 

Net cash used in investing activities was approximately $23,000 and $17,000 for the three months ended March 31, 2024 and 2023, respectively. The cash outflow in 2024 was attributable to the purchase of a new car for our fleet. The cash outflow in 2023 was attributable to the purchase of pharmacy equipment.

 

Net cash used in financing activities was approximately $0.1 million for both the three months ended March 31, 2024 and 2023, due to the payments made on notes payable and finance leases.

 

Liquidity and Capital Resources

 

We have an accumulated deficit of approximately $34.8 million and $34.4 million as of March 31, 2024 and December 31, 2023, respectively. We have spent, and expect to continue to spend, additional amounts in connection with implementing our business strategy.

 

For the three months ended March 31, 2024, we had a net loss of approximately $0.4 million and a decrease in net cash position of approximately $2.4 million. The Company’s cash position was approximately $5.5 million as of March 31, 2024.

 

On May 5, 2023, the Company and NextPlat entered into a First Amendment (the “Amendment”) to that certain Securities Purchase Agreement dated November 16, 2022 (the “Debenture Purchase Agreement”). Under the Debenture Purchase Agreement, we agreed to issue, and NextPlat agreed to purchase, from time to time during the three-year term of the Debenture Purchase Agreement, up to an aggregate of $10 million of secured convertible debentures from NextPlat (the “Debentures”). Pursuant to the Amendment, NextPlat and the Company agreed to amend the Debenture Purchase Agreement and the form of Debenture attached as an exhibit thereto to have a conversion price of $2.20 per share. As of the date these consolidated financial statements were issued, no Debentures have been purchased by NextPlat under the Debenture Purchase Agreement.

 

Management believes that the above transactions, along with our present cash position and the cash we expect to generate from operating activities, will allow us to operate and meet our obligations for at least 12 months from the issuance date of these consolidated financial statements.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2024, we had no material off-balance sheet arrangements or obligations that have or are reasonably likely to have a current or future effect on our financial condition, change in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

 

Recent Accounting Pronouncements

 

The most recently adopted accounting pronouncements and accounting pronouncements to be adopted by the Company are described in Note 3 in the Notes to our Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

 

8

---

Table of Contents

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, for this reporting period and are not required to provide the information required under this Item.

 

ITEM 4.

CONTROLS AND PROCEDURES

 

(a) Evaluation of disclosure controls and procedures. Based on management’s evaluation (with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO)), as of the end of the period covered by this report, our CEO and CFO have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), were not effective due to the material weakness described below to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

(b) Inherent Limitations on Controls. Management, including the CEO and CFO, does not expect that our disclosure controls and procedures will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

 

Previously Reported Material Weakness in Internal Controls Over Financial Reporting

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis. As disclosed in Part II Item 9A. “Controls and Procedures” in our annual report on Form 10-K for the year ended December 31, 2023, during fiscal year 2023 we identified a material weakness in our internal control over financial reporting. The material weakness is related to the improper accounting for the change in deferred tax valuation allowances resulting from the July 1, 2023 business combination without transfer of consideration. This material weakness also arises from our lack of personnel with an appropriate level of knowledge and experience in accounting for complex or non-routine transactions. Subsequent to the identification of this material weakness, we conducted additional procedures and determined that there was no material misstatement in our consolidated financial statements for the year ended December 31, 2023.

 

Remediation of Previously Reported Material Weakness

 

During the three months ended March 31, 2024, we took the following measures as part of our previously disclosed remediation plan: a.) providing education and training to senior accounting staff as it relates to complex and non-routine transactions; and b.) consulting with accounting and tax experts to provide appropriate guidance with the accounting for complex and non-routine transactions.

 

We are committed to ensuring that our internal control over financial reporting is designed and operating effectively. We are continuing to test the design of the new and enhanced controls related to the previously reported material weakness over the review of complex or non-routine transactions. We believe that these new and enhanced controls will be fully implemented and validated by the end of the third quarter of 2024. However, the material weakness will not be considered remediated until the new and enhanced controls have been operating effectively for a sufficient period of time.

 

(c) Changes in internal controls over financial reporting. Other than as discussed above, there has been no change in our internal control over financial reporting during our fiscal quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

 

9

---

Table of Contents

 

PART II – OTHER INFORMATION

 

ITEM 1.

LEGAL PROCEEDINGS

 

None.

 

ITEM 1A.

RISK FACTORS

 

Investors should carefully consider the risks in the “Risk Factors” in Part 1: Item 1A of our 2023 Form 10-K, and our other filings with the SEC. These risks are not the only ones facing the Company. Additional risks not currently known to us or that we currently believe are immaterial may also impair our business operations. Any of these risks could adversely affect our business, cash flows, financial condition, and results of operations. The trading price of our common stock could fluctuate due to any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q. There have been no material changes in our risk factors from those discussed in our 2023 Form 10-K. 

 

ITEM 2.

UNREGISTERED SALE OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

 

On January 2, 2024, the Company issued 15,923 shares of common stock valued at $49,998, or $3.14 per share, to Joseph Ziegler pursuant to a Directors Agreements dated December 9, 2021.

 

On January 25, 2024, the Company issued 2,027 shares of common stock valued at $15,000, or $7.40 per share, to an employee as stock-based compensation.

 

During the three months ended March 31, 2024, there were no repurchases of our common stock.

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4.

MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

ITEM 5.

OTHER INFORMATION

 

Rule 10b5-1 Trading Arrangement

 

During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

10

---

Table of Contents

 

 

ITEM 6.

EXHIBITS

 

31.1	Certification of Chairman and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chairman and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its Inline XBRL tags are embedded within the Inline XBRL document.
101	The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

 

11

---

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Progressive Care Inc.
Date: May 15, 2024	By:	/s/ Charles M. Fernandez
		Charles M. Fernandez Chief Executive Officer
		(Principal Executive Officer)
Date: May 15, 2024	By:	/s/ Cecile Munnik
		Cecile Munnik Chief Financial Officer (Principal Financial and Accounting Officer)

 

12

Exhibit 31.1

 

PROGRESSIVE CARE INC.

CERTIFICATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Charles M. Fernandez, certify that:

 

1.	I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2024, of Progressive Care Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including the registrant’s consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2024

 

/s/ Charles M. Fernandez
Charles M. Fernandez Chairman and Chief Executive Officer
(Principal Executive Officer)

 

 

Exhibit 31.2

 

PROGRESSIVE CARE INC.

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Cecile Munnik, certify that:

 

1.	I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2024, of Progressive Care Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including the registrant’s consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2024

 

/s/ Cecile Munnik
Cecile Munnik Chief Financial Officer
(Principal Financial and Accounting Officer)

 

 

Exhibit 32.1

 

PROGRESSIVE CARE INC.

CERTIFICATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER PURSUANT TO

18 U.S.C SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Progressive Care Inc. (“Progressive Care”) on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles M. Fernandez, Chairman and Chief Executive Officer of Progressive Care Inc., certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 15, 2024

 

/s/ Charles M. Fernandez
Charles M. Fernandez Chairman and Chief Executive Officer
(Principal Executive Officer)

 

 

Exhibit 32.2

 

PROGRESSIVE CARE INC.

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

18 U.S.C SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Progressive Care Inc. (“Progressive Care”) on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecile Munnik, Chief Financial Officer of Progressive Care Inc., certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 15, 2024

 

/s/ Cecile Munnik
Cecile Munnik Chief Financial Officer
(Principal Financial and Accounting Officer)

 

 

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Document Information [Line Items]
Entity Central Index Key	0001402945
Entity Registrant Name	Progressive Care Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-52684
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0186005
Entity Address, Address Line One	400 Ansin Blvd., Suite A
Entity Address, City or Town	Hallandale Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33009
City Area Code	305
Local Phone Number	760-2053
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,240,731

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 5,544	$ 7,895
Accounts receivable – trade, net	12,253	8,339
Receivables - other, net	2,068	1,846
Inventory, net	3,385	3,069
Prepaid expenses	185	334
Total Current Assets	23,435	21,483
Property and equipment, net	3,220	3,284
Other Assets
Goodwill	731	731
Intangible assets, net	13,706	14,398
Operating right-of-use assets, net	249	427
Finance right-of-use assets, net	18	22
Deposits	39	39
Total Other Assets	14,743	15,617
Total Assets	41,398	40,384
Current Liabilities
Accounts payable and accrued liabilities	13,555	12,158
Notes payable	144	145
Operating lease liabilities	159	170
Finance lease liabilities	20	18
Total Current Liabilities	13,878	12,491
Long-term Liabilities
Notes payable, net of current portion	1,081	1,110
Operating lease liabilities, net of current portion	182	214
Finance lease liabilities, net of current portion	0	5
Total Liabilities	15,141	13,820
Commitments and Contingencies
Stockholders’ Equity
Common stock ($0.0001 par value, 100,000,000 shares authorized; 6,240,731 and 6,222,781 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)	67	67
Additional paid-in capital	60,951	60,886
Accumulated deficit	(34,761)	(34,389)
Total Stockholders’ Equity	26,257	26,564
Total Liabilities and Stockholders’ Equity	41,398	40,384
Series A Preferred Stock [Member]
Stockholders’ Equity
Preferred Stock	0	0
Series B Preferred Stock [Member]
Stockholders’ Equity
Preferred Stock	$ 0	$ 0

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, shares authorized (in shares)	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,240,731	6,222,781
Common stock, shares outstanding (in shares)	6,240,731	6,222,781
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	51	51
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	100,000	100,000
Preferred stock, shares issued (in shares)	3,000	3,000
Preferred stock, shares outstanding (in shares)	3,000	3,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024		Mar. 31, 2023
Revenues, net	$ 14,628		$ 11,392
Costs of revenue	10,623		8,245
Gross profit	4,005		3,147
Operating expenses
Salaries and wages	2,116		1,598
Professional fees	478		774
Depreciation and amortization	776		64
Selling, general, and administrative	900		697
Impairment loss	132	[1]	0
Total operating expenses	4,402		3,133
(Loss) income from operations	(397)		14
Other income (expense):
Gain on sale or disposal of property and equipment	1		0
Interest income	40		6
Interest expense	(16)		(150)
Total other income (expense)	25		(144)
Loss before income taxes	(372)		(130)
Provision for income taxes	0		0
Net loss attributable to common shareholders	$ (372)		$ (130)
Basic and diluted weighted average loss per common share (in dollars per share)	$ (0.06)		$ (0.04)
Weighted average number of common shares outstanding during the period – basic and diluted (in shares)	6,240		3,356
Product [Member]
Revenues, net	$ 11,255		$ 9,794
Costs of revenue	10,560		8,196
Service [Member]
Revenues, net	3,373		1,598
Costs of revenue	$ 63		$ 49
[1] Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	0	3	3,347
Balance at Dec. 31, 2022	$ 0	$ 0	$ 67	$ 22,525	$ (14,974)	$ 7,618
Stock-based compensation (in shares)	0	0	11
Stock-based compensation	$ 0	$ 0	$ 0	50	0	50
Net loss for the three months ended March 31, 2024	$ 0	$ 0	$ 0	0	(130)	(130)
Balance (in shares) at Mar. 31, 2023	0	3	3,358
Balance at Mar. 31, 2023	$ 0	$ 0	$ 67	22,575	(15,104)	7,538
Balance (in shares) at Dec. 31, 2023	0	3	6,223
Balance at Dec. 31, 2023	$ 0	$ 0	$ 67	60,886	(34,389)	26,564
Stock-based compensation (in shares)	0	0	18
Stock-based compensation	$ 0	$ 0	$ 0	65	0	65
Net loss for the three months ended March 31, 2024	$ 0	$ 0	$ 0	0	(372)	(372)
Balance (in shares) at Mar. 31, 2024	0	3	6,241
Balance at Mar. 31, 2024	$ 0	$ 0	$ 67	$ 60,951	$ (34,761)	$ 26,257

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024		Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (372)		$ (130)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation	79		44
Change in provision for doubtful accounts	2		9
Amortization of debt issuance costs and debt discounts	0		96
Stock-based compensation	65		60
Amortization of right-of-use assets - finance leases	5		8
Amortization of right-of-use assets - operating leases	44		36
Change in accrued interest on notes payable	0		34
Amortization of intangible assets	692		12
Gain on sale or disposal of property and equipment	(1)		0
Impairment loss	132	[1]	0
Changes in operating assets and liabilities:
Accounts receivable	(4,138)		(378)
Grant receivable	0		(277)
Inventory	(316)		(550)
Prepaid expenses	149		19
Deposits	0		(1)
Accounts payable and accrued liabilities	1,423		1,885
Operating lease liabilities	(41)		(40)
Net cash (used in) provided by operating activities	(2,277)		827
Cash flows from investing activities:
Purchase of property and equipment	(24)		(17)
Proceeds from sale or disposal of property and equipment	1		0
Net cash used in investing activities	(23)		(17)
Cash flows from financing activities:
Payments on notes payable	(46)		(91)
Payments on finance lease liabilities	(5)		(10)
Net cash used in financing activities	(51)		(101)
(Decrease) increase in cash	(2,351)		709
Cash at beginning of period	7,895		6,743
Cash at end of period	5,544		7,452
Supplemental disclosures of cash flow information:
Cash paid for interest	16		19
Cash paid for income taxes	$ 0		$ 0
[1] Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Note 1 - Organization & Nature of Operations	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1. Organization and Nature of Operations   Progressive Care Inc. (“Progressive”) was incorporated under the laws of the state of Delaware on October 31, 2006.   Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901”), Touchpoint RX, LLC doing business as Pharmco Rx 1002, LLC (“Pharmco 1002”), Family Physicians RX, Inc. doing business as PharmcoRx 1103 and PharmcoRx 1204 (“FPRX” or “Pharmco 1103” and “Pharmco 1204”) (pharmacy subsidiaries collectively referred to as “Pharmco”), and ClearMetrX Inc. (“ClearMetrX”) is a personalized healthcare services company that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers.   Pharmco 901 was formed on November 29, 2005 as a Florida Limited Liability Company and is a 100% owned subsidiary of Progressive. Pharmco 901 was acquired by Progressive on October 21, 2010. We currently deliver prescriptions to Florida’s diverse population and ship medications to patients in states where we hold non-resident pharmacy licenses as well. We currently hold Florida Community Pharmacy Permits at all Florida pharmacy locations and our Pharmco 901 location is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Illinois, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah. We are able to dispense to patients in the state of Massachusetts without a non-resident pharmacy license because Massachusetts does not require such a license for these activities.   Pharmco 1103 is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides Pharmco’s pharmacy services to Miami-Dade County, Broward County, the Orlando/Tampa corridor, and the Treasure Coast of Florida. Progressive acquired all the ownership interests in Pharmco 1103 in a purchase agreement entered into on June 1, 2019.   Pharmco 1002 is a pharmacy located in Palm Springs, Florida that provides Pharmco’s pharmacy services to Palm Beach, St. Lucie and Martin Counties, Florida. Progressive acquired all the ownership interests in Pharmco 1002 in a purchase agreement entered into on July 1, 2018.   ClearMetrX was formed on June 10, 2020 and provides third-party administration (“TPA”) services to 340B covered entities. ClearMetrX also provides data analytics and reporting services to support and improve care management for health care organizations.   RXMD Therapeutics was formed on October 1, 2019. RXMD Therapeutics has had no operating activity to date.   We have organized our operations into two reportable segments: Pharmacy Operations and TPA. See “Note 15. Reportable Segments.”   On June 30, 2023, NextPlat Corp (“NextPlat”), Charles M. Fernandez, Chairman and Chief Executive Officer of the Company, and Rodney Barreto, Vice-Chairman of the Company, entered into a voting agreement whereby at any annual or special shareholders meeting of the Company’s stockholders Messrs. Fernandez and Barreto agreed to vote all of the common stock shares that they own in the same manner that NextPlat votes its Common Stock and equivalents. On July 1, 2023, NextPlat and Messrs. Fernandez and Barreto exercised common stock purchase warrants and were issued 632,269, 211,470, and 130,571 common stock shares, respectively, by the Company. After the exercise of the common stock purchase warrants, NextPlat and Messrs. Fernandez and Barreto collectively owned 53% of the Company’s voting common stock. Collectively, the exercise of the common stock purchase warrants and the entry into the voting agreement constituted a change in control in Progressive Care. As a result of the change in control, NextPlat was deemed the accounting acquirer in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations and elected to apply push-down accounting. The application of push-down accounting created a new basis of accounting for all assets and liabilities based on their fair value at the date of acquisition, with few exceptions permissible under GAAP. As a result, the Company’s financial position, results of operations, and cash flows subsequent to the acquisition on July 1, 2023 have been segregated to indicate pre-acquisition and post-acquisition periods. The pre-acquisition period through June 30, 2023 is referred to as the “Predecessor Company”. The post-acquisition period, July 1, 2023 and forward, includes the impact of push-down accounting and is referred to as the “Successor Company”.

Note 2 - Basis of Presentation and Principles of Consolidation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2. Basis of Presentation and Principles of Consolidation   The accompanying Unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) on a basis consistent with reporting interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements.   Interim results are not necessarily indicative of the results that may be expected for the full year. Accordingly, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statements and notes thereto included in the 2023 Form 10-K. In the opinion of management, the Unaudited Condensed Consolidated Financial Statements contain all adjustments (consisting principally of normal recurring accruals) necessary for a fair presentation of the condensed consolidated balance sheets, statements of operations, statements of stockholders’ equity and statements of cash flows for such interim periods presented.   The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Certain 2023 financial information has been reclassified to conform to the 2024 presentation. Such reclassifications do not impact the Company’s previously reported financial position or net income (loss). On the Condensed Consolidated Statements of Operations, Revenues, net, Costs of revenue, and Operating expenses have been disaggregated for the three months ended March 31, 2023.

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. Summary of Significant Accounting Policies   The significant accounting policies of the Company were described in Note 3 to the Audited Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to the Company’s significant accounting policies for the three months ended March 31, 2024.    Cash   The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may exceed federally insured limits of $250,000. The Company had approximately $0.5 million that was uninsured as of  March 31, 2024. In July 2023, the Company entered into a deposit placement agreement for Insured Cash Sweep Services (“ICS”). This service is a secure and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000.   Concentrations   Suppliers:   The Company had significant concentrations with one vendor. The purchases from this significant vendor were 98% and 96% of total vendor purchases for the three months ended March 31, 2024 (Successor period) and the three months ended March 31, 2023 (Predecessor period), respectively.   Customers:   The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three most significant PBMs were as follows:       Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   A     33 %     —   B     21 %     1 % C     16 %     53 %   Direct and Indirect Remuneration (“DIR”) Fees   DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, for some PBMs, DIR fees were charged at the time of the settlement of a pharmacy claim. Other PBMs do not determine DIR fees at the claim settlement date, and therefore DIR fees are collected from pharmacies after claim settlement, often as clawbacks of reimbursements based on factors that vary from plan to plan. For example, two PBMs calculate DIR fees on a trimester basis and charge the Company for these fees as reductions of reimbursements paid to the Company two to three months after the end of the trimester (e.g., DIR fees for January – April 20xx claims were clawback by these PBMs in July – August 20xx). As of December 31, 2023, DIR fees that were not collected at the time of claim settlement, the Company recorded an accrued liability for estimated DIR fees that are expected to be collected by the PBMs by the end of the second quarter of 2024. The estimated liability for these fees is highly subjective and the actual amount collected may differ from the accrued liability. The uncertainty of management’s estimates is due to inadequate disclosure to the Company by the PBMs as to exactly how these fees are calculated either at the time the DIR fees are actually assessed and reported to the Company. The detail level of the disclosure of assessed DIR fees varies based on the information provided by the PBM. Effective January 1, 2024, all PBMs began charging DIR fees at the time of the settlement of a pharmacy claim.   Recently Adopted Accounting Standards   None.   Accounting Pronouncements Issued but not yet Adopted   In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. ASU 2023-07 is required to be adopted for annual periods beginning after December 15, 2023, and interim period within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company will adopt the standard in its interim reporting beginning with Q1-2025, and the Company will adopt the standard in its annual reporting for the year ending December 31, 2024. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements but will enhance our current disclosures.   In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740)—Improvements to Income Tax Disclosure” (“ASU 2023-09”), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. ASU 2023-09 is required to be adopted for annual periods beginning after December 15, 2024, with early adoption permitted. The Company will adopt this accounting standard update effective January 1, 2025. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements.   Subsequent Events   Merger Agreement   On April 12, 2024, the Company entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”) with NextPlat Corp, a Nevada corporation (“Parent”) and Progressive Care LLC, a Nevada limited liability company and a direct, wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Parent and the Company will enter into a business combination transaction pursuant to which the Company will merge with and into Merger Sub (the “Merger”) at the effective time of the Merger (the “Effective Time”), with Merger Sub being the surviving entity of the Merger.   The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three of the Company’s independent directors, each of whom does not have an interest in such transaction. The Merger Agreement was also approved by a special committee of Parent’s board of directors, which was affirmed by the entirety of Parent’s board of directors, as well as the sole member of Merger Sub.   Lock-Up Agreements   On April 9, 2024, the Company entered into lock-up agreements with each of its directors and executive officers (the “Company Lock-Up Agreements”). Additionally, separate lock-up agreements were established between the Company and the directors and executive officers of Parent (the “Parent Lock-Up Agreements”). Notably, individuals serving roles in both the Company and Parent, such as Charles M. Fernandez, Cecile Munnik, and Rodney Barreto, were covered by a single lock-up agreement with the Company relating to each of their shares in both the Company and Parent (the “Hybrid Lock-Up Agreements”, together with the Company Lock-Up Agreements and Parent Lock-Up Agreements, the “Lock-Up Agreements”). All Lock-Up Agreements prohibit the aforementioned stockholders from selling, transferring, acquiring or purchasing any of the securities of either the Company or Parent during the Interim Period. Notwithstanding the Lock-Up Agreements, the directors of the Company will continue to receive shares of the Company common stock payable to such director as compensation pursuant to the terms of his or her director services agreement.

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Fair Value Measurements   Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:   Level 1: Quoted prices in active markets for identical assets or liabilities.   Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.   The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:     ● Cash, accounts receivable, and accounts payable and accrued liabilities: The amounts reported in the accompanying Condensed Consolidated Balance Sheets approximate fair value due to their short-term nature.     ● Notes payable and lease liabilities: The carrying amount of notes payable approximated fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing. The carrying value of lease liabilities approximated fair value due to the implicit rate in the lease in relation to the Company’s borrowing rate and the duration of the leases (Level 2 inputs).   Fair Value Measurement on a Nonrecurring Basis   Common Stock Purchase Warrants   As of March 31, 2024, the Company had common stock purchase warrants classified as Level 3 equity instruments. The fair value of the common stock purchase warrants on the date of issuance was approximately $4.6 million. The Company used the Monte Carlo simulation model for valuation of the common stock purchase warrants. Key inputs into the Monte Carlo simulation model were as follows at the valuation date: risk-free interest rate: 3.5%-3.7%; expected term: 3-5.6 years; expected volatility: 93%-102%; exercise price: $2.20. For additional information on the initial issuance and subsequent exercise of the common stock purchase warrants, see also “Note 13. Stockholder’s Equity, Common Stock and Common Stock Purchase Warrants.”

Note 5 - Revenue	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5. Revenue   The following table disaggregates net revenues by categories (in thousands):       Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   Sales of products, net                 Prescription revenue, net of PBM fees   $ 11,324     $ 9,771   COVID-19 testing revenue     —       45   Subtotal     11,324       9,816   Revenues from services:                 340B contract revenue     3,304       1,576   Revenues, net   $ 14,628     $ 11,392

Note 6 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6. Earnings (Loss) per Share   Basic earnings per share is computed by dividing net (loss) income available to common shareholders by the weighted average number of common shares outstanding during the year, excluding the effects of any potentially dilutive securities. Diluted earnings per share gives effect to all potentially dilutive shares of common stock outstanding during the year including common stock purchase warrants and stock options, using the treasury stock method, and convertible debt, using the if converted method. Diluted earnings per share excludes all dilutive potential of shares of common stock if their effect is anti-dilutive.   The components of basic and diluted EPS were as follows (in thousands, except per share data). For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted loss per common share and basic loss per common share being equivalent.       Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   Net loss attributable to common shareholders   $ (372 )   $ (130 )                   Basic weighted average common shares outstanding     6,240       3,356   Potentially dilutive common shares     —       —   Diluted weighted average common shares outstanding     6,240       3,356                     Basic weighted average loss per common share   $ (0.06 )   $ (0.04 ) Diluted weighted average loss per common share   $ (0.06 )   $ (0.04 )                   Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share:                 Common stock purchase warrants     102,468       60,152   Stock options     59,623       151,937         162,091       212,089

Note 7 - Accounts Receivable - Trade, Net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 7. Accounts Receivable – Trade, net   Accounts receivable consisted of the following (in thousands):     Successor       March 31, 2024     December 31, 2023   Gross accounts receivable – trade   $ 12,527     $ 8,611   Less: allowance for credit losses     (274 )     (272 ) Accounts receivable – trade, net   $ 12,253     $ 8,339     The Successor Company increased the allowance for credit losses in the amount of approximately $2,000 for the three months ended March 31, 2024. The Predecessor Company increased the allowance of credit losses in the amount of approximately $9,000 for the three months ended March 31, 2023.   Accounts receivable – trade, net for the Predecessor Company as of January 1, 2023 and  March 31, 2023 were approximately $3.4 million and $4.3 million, respectively.

Note 8 - Receivables - Other, net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 8. Receivables – Other, net   Receivables – Other, net consisted of the following (in thousands):     Successor       March 31, 2024     December 31, 2023   Performance bonuses   $ 1,859     $ 1,602   Customers     179       192   Other     30       52       $ 2,068     $ 1,846     Performance bonuses, paid annually by PBMs, are estimated based on historical pharmacy performance and prior payments received. Other receivables are loans to employees.

Note 9 - Property and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 9. Property and Equipment, net   Property and equipment, net consisted of the following (in thousands):             Successor       Estimated Useful Life     March 31, 2024     December 31, 2023   Building   40 years     $ 2,116     $ 2,116   Vehicles   3 - 5 years       585       595   Furniture and equipment   5 years       388       388   Land     ---       184       184   Leasehold improvements and fixtures   Lesser of estimated useful life or life of lease       119       76   Computer equipment   3 years       39       39   Construction in progress     ---       —       22   Total             3,431       3,420   Less: accumulated depreciation             (211 )     (136 ) Property and equipment, net           $ 3,220     $ 3,284     Depreciation expense for the Successor Company was approximately $79,000 for the three months ended March 31, 2024. Depreciation expense for the Predecessor Company was approximately $44,000 for the three months ended March 31, 2023.

Note 10 - Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 10. Goodwill and Intangible Assets   Goodwill   Goodwill was approximately $0.7 million as of March 31, 2024 and December 31, 2023 (Successor periods), and was allocated to the TPA reporting segment. There were no changes in the carrying amount of goodwill during the three months ended March 31, 2024.   Intangible Assets   Intangible assets consisted of the following (in thousands):       Successor       March 31, 2024     December 31, 2023       Gross amount   Accumulated amortization     Net Amount     Gross amount   Accumulated amortization     Net Amount   Pharmacy records   $ 8,130   $ (1,219 )   $ 6,911     $ 8,130   $ (807 )   $ 7,323   Tradenames     4,700     (353 )     4,347       4,700     (224 )     4,476   Developed technology     2,880     (432 )     2,448       2,880     (281 )     2,599   Total intangible assets   $ 15,710   $ (2,004 )   $ 13,706     $ 15,710   $ (1,312 )   $ 14,398     Amortization of intangible assets for the Successor Company was approximately $0.7 million for the three months ended March 31, 2024. Amortization of intangible assets for the Predecessor Company was approximately $12,000 for the three months ended March 31, 2023.   The following table represents the total estimated future amortization of intangible assets for the five succeeding years and thereafter as of March 31, 2024 (in thousands):       Successor   Year   Amount   2024 (remaining nine months)   $ 2,004   2025     2,672   2026     2,672   2027     2,672   2028     1,571   Thereafter     2,115   Total   $ 13,706

Note 11 - Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 11. Accounts Payable and Accrued Liabilities   Accounts payable and accrued liabilities consisted of the following (in thousands):       Successor       March 31, 2024     December 31, 2023   Accounts payable – trade   $ 12,752     $ 11,256   Accrued payroll and payroll taxes     356       167   Accrued PBM fees     366       571   Other accrued liabilities     81       164   Total   $ 13,555     $ 12,158

Note 12 - Notes Payable	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 12. Notes Payable   Notes payable consisted of the following (in thousands):       Successor       March 31, 2024     December 31, 2023   A. Mortgage note payable - commercial bank - collateralized   $ 1,118     $ 1,140   B. Note payable - uncollateralized     25       25   C. Notes payable - collateralized     82       90   Subtotal     1,225       1,255   Less: current portion of notes payable     (144 )     (145 ) Long-term portion of notes payable   $ 1,081     $ 1,110     The corresponding notes payable above are more fully discussed below:   (A) Mortgage Note Payable – collateralized   In 2018, Pharmco 901 closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $1,530,000. The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on December 14, 2028 and is subject to a prepayment penalty. Principal and interest will be repaid through 119 regular payments of $11,901 that began in January 2019, with the final payment of all principal and accrued interest not yet paid on December 14, 2028. Note repayment is guaranteed by Progressive Care Inc.   (B) Note Payable – Uncollateralized   As of March 31, 2024 and December 31, 2023, the uncollateralized note payable represents a noninterest-bearing loan that is due on demand from an investor.   (C) Notes Payable – Collateralized   In April 2021, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $30,000. During September 2021, pharmacy equipment was returned since the installation was cancelled and the note was amended. The amended promissory note payable requires 46 monthly payments of $331, including interest at 6.9%. The balance outstanding as of March 31, 2024 and December 31, 2023 on the note payable was approximately $5,000 and $6,000, respectively.   In July 2022, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $90,000. The terms of the promissory note payable require 60 monthly payments of $1,859, including interest at 8.78% starting January 2023. The balance outstanding on the note payable was approximately $70,000 and $74,000 as of March 31, 2024 and December 31, 2023, respectively. The promissory note is secured by equipment with a net book value of approximately $68,000 and $71,000 as of March 31, 2024 and December 31, 2023, respectively.   In September 2022, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase a vehicle in the amount of approximately $25,000. The terms of the promissory note payable require 24 monthly payments of $1,143, including interest at 8.29% starting October 2022. The balance outstanding on the note payable was approximately $7,000 and $10,000 as of March 31, 2024 and December 31, 2023, respectively. The promissory note is secured by the vehicle with a net book value of approximately $17,000 and $18,000 as of March 31, 2024 and December 31, 2023, respectively.   Principal outstanding as of March 31, 2024, is expected to be repayable as follows (in thousands):       Successor   Year   Amount   2024 (remaining nine months)   $ 115   2025     114   2026     119   2027     124   2028     753   Total   $ 1,225     Interest expense on these notes payable for the Successor Company was approximately $16,000 for the three months ended March 31, 2024. Interest expense on notes payable, exclusive of debt discount and debt issue cost amortization, for the Predecessor Company was approximately $51,000 for the three months ended March 31, 2023.

Note 13 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Equity [Text Block]	Note 13. Stockholders’ Equity   Preferred Stock   The Company has 10,000,000 shares of preferred stock authorized. As of March 31, 2024 and December 31, 2023, 51 shares are designated as Series A Preferred Stock, par value $0.001 per share, 100,000 shares are designated as Series B Preferred Stock, par value $0.0001 per share, and 9,899,949 shares are undesignated preferred shares, par value $0.0001 per share.   Series A Preferred Stock - Predecessor Company   The Series A preferred stock is a non-dividend producing instrument that ranks superior to the Company’s common stock. Each one (1) share of the Series A Preferred Stock shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding common stock and Preferred Stock eligible to vote at the time of the respective vote (the “Numerator”), divided by (y) 0.49, minus (z) the Numerator.   With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Series A Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.   In July 2014, the board of directors approved the issuance of 51 shares of the Company’s Series A Preferred Stock to a certain employee of the Company, which is equal to 50.99% of the total voting power of all issued and outstanding voting capital of the Company in satisfaction of $20,000 in past due debt. In October 2020, the preferred shares were transferred to a trust whose beneficiary is related to the employee. In August 2022, the Company entered into a Share Exchange Agreement with the trust in which the 51 shares of the Company’s Series A Preferred Stock were acquired from the trust and cancelled in exchange for the issuance of 127,564 shares of the Company’s common stock.   Series B Convertible Preferred Stock - Predecessor Company   On August 30, 2022, the  Company entered into a Securities Purchase Agreement with NextPlat wherein the Company sold 3,000 units, generating gross proceeds of $6.0 million. Each unit is made up of one share of Series B Convertible Preferred Stock, $0.0001 par value, and Investor Warrants. Each warrant entitles the holder to purchase one share of Series B Convertible Preferred Stock at an exercise price of $2,000. The Investor Warrants may also be exercised, in whole or in part, by means of a cashless exercise. The Series B Convertible Preferred Stock has a stated value of $2,000 per share and each Preferred Stock share has the equivalent voting rights of 500 common stock shares. Each share of Series B Convertible Preferred Stock is convertible at any time at the option of the holder into shares of the Company’s common stock determined by dividing the stated value by the conversion price which is $4.00. The Company incurred offering costs associated with the transaction of approximately $1.0 million.   The Series B Convertible Preferred Stock ranks senior to our common stock as to distribution of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The shares of Series B Convertible Preferred Stock shall have a liquidation preference to all other classes of stock of the Company in the amount of $2,000 per share. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series B Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company (i) $2,000 per share plus (ii) the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock which amounts shall be paid pari passu with all holders of common stock.   With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.    Common Stock and Common Stock Purchase Warrants   On May 5, 2023, the Predecessor Company entered into a Securities Purchase Agreement with NextPlat, pursuant to which NextPlat agreed to purchase 455,000 newly issued units of securities from the Predecessor Company (the “Units”) at a price per Unit of $2.20 for an aggregate purchase price of $1.0 million (the “Unit Purchase”). Each Unit consists of one share of common stock, par value $0.0001 per share, of Progressive Care (“Common Stock”) and one common stock purchase warrant to purchase a share of Common Stock (the “PIPE Warrants”). The PIPE Warrants have a three-year term and will be immediately exercisable. Each PIPE Warrant is exercisable at $2.20 per share of Common Stock. The Predecessor Company received cash proceeds of $880,000, net of placement agent commission of $70,000 and legal fees of $50,000. The Company accounted for the PIPE Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the PIPE Warrants was approximately $1.0 million. On July 1, 2023, NextPlat exercised the PIPE Warrants on a cashless basis and was issued 230,056 common stock shares.   Also on May 5, 2023, the Predecessor Company entered into a Debt Conversion Agreement (“DCA”) with NextPlat and the other Holders of that certain Amended and Restated Secured Convertible Promissory Note, dated as of September 2, 2022, made by the Predecessor Company in the original face amount of approximately $2.8 million (the “Note”). Pursuant to the DCA, NextPlat and the other Holders agreed to modify and convert the total approximately $2.9 million of outstanding principal and accrued and unpaid interest to common stock at a conversion price of $2.20 per share (the “Debt Conversion”). Of the total 1,312,379 shares of common stock issued upon conversion of the Note pursuant to the DCA, NextPlat received 570,599 shares, Charles M. Fernandez, the Company’s Chairman and Chief Executive Officer, received 228,240 shares, and Rodney Barreto, the Company’s Vice-Chairman of the Board of Directors, received 228,240 shares. In addition, each of the Holders also received a common stock purchase warrant to purchase one share of common stock for each share of common stock they received upon conversion of the Note (the “Conversion Warrants”). The Conversion Warrants have a three-year term and will be immediately exercisable. Each Conversion Warrant is exercisable at $2.20 per share of Common Stock. The Company accounted for the Conversion Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Conversion Warrants was approximately $2.7 million. On July 1, 2023, NextPlat and Messrs. Fernandez and Barreto exercised the Conversion Warrants. NextPlat exercised 230,000 Conversion Warrants on a cash basis and paid consideration in the amount of $506,000 and was issued 230,000 common stock shares. NextPlat exercised the remaining 340,599 Conversion Warrants on a cashless basis and was issued 172,213 common stock shares. Messrs. Fernandez and Barreto exercised the Conversion Warrants on a cashless basis and were each issued 115,402 common stock shares. As of March 31, 2024, the fair value of the remaining Conversion Warrants was approximately $0.6 million.   At the same time as the SPA and DCA, the Predecessor Company and NextPlat entered into the Debenture Purchase Agreement. Under the Debenture Purchase Agreement, the Predecessor Company agreed to issue, and NextPlat agreed to purchase, from time to time during the three-year term of the Debenture Purchase Agreement, up to an aggregate of $10.0 million of Debentures to NextPlat. Pursuant to the Amendment, NextPlat and the Predecessor Company agreed to amend the Debenture Purchase Agreement and the form of Debenture to have a conversion price of $2.20 per share. As of March 31, 2024, no Debentures have been purchased by NextPlat under the Debenture Purchase Agreement.   Dawson James Securities, Inc. (the “Placement Agent”) served as placement agent for the Unit Purchase. In consideration for the Placement Agent’s services, the Predecessor Company issued to the Placement Agent and its affiliates warrants to purchase 91,000 shares of Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants have a five-year term and will be exercisable in December 2023. Each Placement Agent Warrant is exercisable at $2.20 per share of Common Stock. The Company accounted for the Placement Agent Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Placement Agent Warrants was approximately $0.2 million.   In addition, the Predecessor Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the “Inducement Warrants”). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three-year term and will be immediately exercisable. Each Inducement Warrant is exercisable at $2.20 per share of Common Stock. The Company accounted for the Inducement Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Inducement Warrants was approximately $0.7 million. On July 1, 2023, Messrs. Fernandez and Barreto exercised the Inducement Warrants on a cashless basis and were issued 96,068 and 15,169 common stock shares, respectively. As of March 31, 2024, the fair value of the remaining Inducement Warrants was approximately $0.2 million.

Note 14 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 14. Stock-Based Compensation   Stock-based compensation is recorded in selling, general, and administrative expenses in the Unaudited Condensed Consolidated Statement of Operations. The Successor Company recorded total stock-based compensation expense of approximately $65,000 for the three months ended March 31, 2024. The Predecessor Company recorded total stock-based compensation expense of approximately $60,000 for the three months ended March 31, 2023. There were no income tax benefits recognized from stock-based compensation during the respective periods due to cumulative losses and valuation allowances.

Note 15 - Reportable Segments	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 15. Reportable Segments   The Company has two reportable segments: (i) Pharmacy Operations, which provides prescription pharmaceuticals, compounded medications, tele-pharmacy services, COVID-19 related diagnostics and vaccinations, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, and contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program and (ii) Third-Party Administration, which provides data management and reporting services to support health care organizations. Operating expenses are reflected in the segment in which the costs are incurred.   Corporate includes certain assets and expenses related to corporate functions that are not specifically attributable to an individual reportable segment, such as legal, public company expenses, tax compliance and senior executive staff.    The Company evaluates the performance of each of the segments based on income (loss) from operations. While the Company believes there are synergies between the two business segments, the segments are managed separately because each requires different business strategies.   The accounting policies used to determine the results of the operating segments are the same as those utilized for the Consolidated Financial Statements as a whole. There are no inter-segment sales or transfers.   The following tables present a summary of net income (loss) of the reportable segments (in thousands):       Successor       Three Months Ended March 31, 2024       Pharmacy Operations     Third-Party Administration     Corporate     Total Consolidated   Sales of products, net   $ 11,255     $ —     $ —     $ 11,255   Revenues from services     2,840       533       —       3,373   Revenues, net     14,095       533       —       14,628                                     Costs of products     10,560       —       —       10,560   Costs of services     —       63       —       63   Costs of revenue     10,560       63       —       10,623                                     Gross profit     3,535       470       —       4,005                                     Operating expenses:                                 Salaries and wages     1,901       33       182       2,116   Professional fees     4       81       393       478   Depreciation and amortization     615       156       5       776   Selling, general, and administrative     770       7       123       900   Impairment loss (1)     132       —       —       132   Total operating expenses     3,422       277       703       4,402   Income (loss) from operations     113       193       (703 )     (397 ) Other (expense) income     (14 )     —       39       25   Income (loss) before income taxes     99       193       (664 )     (372 ) Provision for income taxes     —       —       —       —   Net income (loss)   $ 99     $ 193     $ (664 )   $ (372 ) (1) Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.       Predecessor       Three Months Ended March 31, 2023       Pharmacy Operations     Third-Party Administration     Corporate     Total Consolidated   Sales of products, net   $ 9,794     $ —     $ —     $ 9,794   Revenues from services     1,081       517       —       1,598   Revenues, net     10,875       517       —       11,392                                     Costs of products     8,196       —       —       8,196   Costs of services     —       49       —       49   Costs of revenue     8,196       49       —       8,245                                     Gross profit     2,679       468       —       3,147                                     Operating expenses:                                 Salaries and wages     1,445       33       120       1,598   Professional fees     383       96       295       774   Depreciation and amortization     60       4       —       64   Selling, general, and administrative     588       4       105       697   Total operating expenses     2,476       137       520       3,133   Income (loss) from operations     203       331       (520 )     14   Other expense     (13 )     —       (132 )     (144 ) Income (loss) before income taxes     190       331       (652 )     (130 ) Provision for income taxes     —       —       —       —   Net income (loss)   $ 190     $ 331     $ (652 )   $ (130 )       Pharmacy Operations     Third-Party Administration     Corporate     Eliminations (1)     Total Consolidated   Total Assets as of March 31, 2024 (Successor)   $ 39,439     $ 4,733     $ —     $ (2,774 )   $ 41,398   Total Assets as of December 31, 2023 (Successor)   $ 38,516     $ 4,573     $ 69     $ (2,774 )   $ 40,384   (1) Eliminations consist of investments in subsidiaries between the Pharmacy Operations segment and Corporate.   Capital expenditures for the Pharmacy Operations reporting segment were approximately $0.1 million for the three months ended March 31, 2024 (Successor period). Capital expenditures for the Pharmacy Operations reporting segment were approximately $17,000 for the three months ended March 31, 2023 (Predecessor period). There were no capital expenditures for the TPA reporting segment during the three months ended March 31, 2024 (Successor period) and the three months ended March 31, 2023 (Predecessor period).

Note 16 - Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16. Related Party Transactions   Successor Company   During the three months ended March 31, 2024, the Successor Company paid $60,000 to NextPlat as management fees in accordance with the amended Management Services Agreement (the “Management Agreement”) dated May 1, 2023.   Predecessor Company   On February 1, 2023, the Predecessor Company entered into the Management Agreement with NextPlat Corp to provide certain management and administrative services to the Predecessor Company for $25,000 per month fee. On May 1, 2023, the Management Agreement was amended to update the fee to $20,000 per month. During the three months ended March 31, 2023, the Predecessor Company paid $50,000 to NextPlat as management fees.

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	ITEM 5. OTHER INFORMATION   Rule 10b5-1 Trading Arrangement   During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash   The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may exceed federally insured limits of $250,000. The Company had approximately $0.5 million that was uninsured as of  March 31, 2024. In July 2023, the Company entered into a deposit placement agreement for Insured Cash Sweep Services (“ICS”). This service is a secure and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations   Suppliers:   The Company had significant concentrations with one vendor. The purchases from this significant vendor were 98% and 96% of total vendor purchases for the three months ended March 31, 2024 (Successor period) and the three months ended March 31, 2023 (Predecessor period), respectively.   Customers:   The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three most significant PBMs were as follows:       Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   A     33 %     —   B     21 %     1 % C     16 %     53 %
Renumeration Fees [Policy Text Block]	Direct and Indirect Remuneration (“DIR”) Fees   DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, for some PBMs, DIR fees were charged at the time of the settlement of a pharmacy claim. Other PBMs do not determine DIR fees at the claim settlement date, and therefore DIR fees are collected from pharmacies after claim settlement, often as clawbacks of reimbursements based on factors that vary from plan to plan. For example, two PBMs calculate DIR fees on a trimester basis and charge the Company for these fees as reductions of reimbursements paid to the Company two to three months after the end of the trimester (e.g., DIR fees for January – April 20xx claims were clawback by these PBMs in July – August 20xx). As of December 31, 2023, DIR fees that were not collected at the time of claim settlement, the Company recorded an accrued liability for estimated DIR fees that are expected to be collected by the PBMs by the end of the second quarter of 2024. The estimated liability for these fees is highly subjective and the actual amount collected may differ from the accrued liability. The uncertainty of management’s estimates is due to inadequate disclosure to the Company by the PBMs as to exactly how these fees are calculated either at the time the DIR fees are actually assessed and reported to the Company. The detail level of the disclosure of assessed DIR fees varies based on the information provided by the PBM. Effective January 1, 2024, all PBMs began charging DIR fees at the time of the settlement of a pharmacy claim.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards   None.   Accounting Pronouncements Issued but not yet Adopted   In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. ASU 2023-07 is required to be adopted for annual periods beginning after December 15, 2023, and interim period within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company will adopt the standard in its interim reporting beginning with Q1-2025, and the Company will adopt the standard in its annual reporting for the year ending December 31, 2024. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements but will enhance our current disclosures.   In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740)—Improvements to Income Tax Disclosure” (“ASU 2023-09”), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. ASU 2023-09 is required to be adopted for annual periods beginning after December 15, 2024, with early adoption permitted. The Company will adopt this accounting standard update effective January 1, 2025. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements.   Subsequent Events   Merger Agreement   On April 12, 2024, the Company entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”) with NextPlat Corp, a Nevada corporation (“Parent”) and Progressive Care LLC, a Nevada limited liability company and a direct, wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Parent and the Company will enter into a business combination transaction pursuant to which the Company will merge with and into Merger Sub (the “Merger”) at the effective time of the Merger (the “Effective Time”), with Merger Sub being the surviving entity of the Merger.   The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three of the Company’s independent directors, each of whom does not have an interest in such transaction. The Merger Agreement was also approved by a special committee of Parent’s board of directors, which was affirmed by the entirety of Parent’s board of directors, as well as the sole member of Merger Sub.   Lock-Up Agreements   On April 9, 2024, the Company entered into lock-up agreements with each of its directors and executive officers (the “Company Lock-Up Agreements”). Additionally, separate lock-up agreements were established between the Company and the directors and executive officers of Parent (the “Parent Lock-Up Agreements”). Notably, individuals serving roles in both the Company and Parent, such as Charles M. Fernandez, Cecile Munnik, and Rodney Barreto, were covered by a single lock-up agreement with the Company relating to each of their shares in both the Company and Parent (the “Hybrid Lock-Up Agreements”, together with the Company Lock-Up Agreements and Parent Lock-Up Agreements, the “Lock-Up Agreements”). All Lock-Up Agreements prohibit the aforementioned stockholders from selling, transferring, acquiring or purchasing any of the securities of either the Company or Parent during the Interim Period. Notwithstanding the Lock-Up Agreements, the directors of the Company will continue to receive shares of the Company common stock payable to such director as compensation pursuant to the terms of his or her director services agreement.

Note 3 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   A     33 %     —   B     21 %     1 % C     16 %     53 %

Note 5 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   Sales of products, net                 Prescription revenue, net of PBM fees   $ 11,324     $ 9,771   COVID-19 testing revenue     —       45   Subtotal     11,324       9,816   Revenues from services:                 340B contract revenue     3,304       1,576   Revenues, net   $ 14,628     $ 11,392

Note 6 - Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Successor     Predecessor       Three Months Ended March 31, 2024     Three Months Ended March 31, 2023   Net loss attributable to common shareholders   $ (372 )   $ (130 )                   Basic weighted average common shares outstanding     6,240       3,356   Potentially dilutive common shares     —       —   Diluted weighted average common shares outstanding     6,240       3,356                     Basic weighted average loss per common share   $ (0.06 )   $ (0.04 ) Diluted weighted average loss per common share   $ (0.06 )   $ (0.04 )                   Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share:                 Common stock purchase warrants     102,468       60,152   Stock options     59,623       151,937         162,091       212,089

Note 7 - Accounts Receivable - Trade, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Successor       March 31, 2024     December 31, 2023   Gross accounts receivable – trade   $ 12,527     $ 8,611   Less: allowance for credit losses     (274 )     (272 ) Accounts receivable – trade, net   $ 12,253     $ 8,339

Note 8 - Receivables - Other, net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Other Receivables, Net [Table Text Block]	Successor       March 31, 2024     December 31, 2023   Performance bonuses   $ 1,859     $ 1,602   Customers     179       192   Other     30       52       $ 2,068     $ 1,846

Note 9 - Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	Successor       Estimated Useful Life     March 31, 2024     December 31, 2023   Building   40 years     $ 2,116     $ 2,116   Vehicles   3 - 5 years       585       595   Furniture and equipment   5 years       388       388   Land     ---       184       184   Leasehold improvements and fixtures   Lesser of estimated useful life or life of lease       119       76   Computer equipment   3 years       39       39   Construction in progress     ---       —       22   Total             3,431       3,420   Less: accumulated depreciation             (211 )     (136 ) Property and equipment, net           $ 3,220     $ 3,284

Note 10 - Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Successor       March 31, 2024     December 31, 2023       Gross amount   Accumulated amortization     Net Amount     Gross amount   Accumulated amortization     Net Amount   Pharmacy records   $ 8,130   $ (1,219 )   $ 6,911     $ 8,130   $ (807 )   $ 7,323   Tradenames     4,700     (353 )     4,347       4,700     (224 )     4,476   Developed technology     2,880     (432 )     2,448       2,880     (281 )     2,599   Total intangible assets   $ 15,710   $ (2,004 )   $ 13,706     $ 15,710   $ (1,312 )   $ 14,398
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Successor   Year   Amount   2024 (remaining nine months)   $ 2,004   2025     2,672   2026     2,672   2027     2,672   2028     1,571   Thereafter     2,115   Total   $ 13,706

Note 11 - Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Successor       March 31, 2024     December 31, 2023   Accounts payable – trade   $ 12,752     $ 11,256   Accrued payroll and payroll taxes     356       167   Accrued PBM fees     366       571   Other accrued liabilities     81       164   Total   $ 13,555     $ 12,158

Note 12 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Debt [Table Text Block]	Successor       March 31, 2024     December 31, 2023   A. Mortgage note payable - commercial bank - collateralized   $ 1,118     $ 1,140   B. Note payable - uncollateralized     25       25   C. Notes payable - collateralized     82       90   Subtotal     1,225       1,255   Less: current portion of notes payable     (144 )     (145 ) Long-term portion of notes payable   $ 1,081     $ 1,110
Schedule of Maturities of Long-Term Debt [Table Text Block]	Successor   Year   Amount   2024 (remaining nine months)   $ 115   2025     114   2026     119   2027     124   2028     753   Total   $ 1,225

Note 15 - Reportable Segments (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Successor       Three Months Ended March 31, 2024       Pharmacy Operations     Third-Party Administration     Corporate     Total Consolidated   Sales of products, net   $ 11,255     $ —     $ —     $ 11,255   Revenues from services     2,840       533       —       3,373   Revenues, net     14,095       533       —       14,628                                     Costs of products     10,560       —       —       10,560   Costs of services     —       63       —       63   Costs of revenue     10,560       63       —       10,623                                     Gross profit     3,535       470       —       4,005                                     Operating expenses:                                 Salaries and wages     1,901       33       182       2,116   Professional fees     4       81       393       478   Depreciation and amortization     615       156       5       776   Selling, general, and administrative     770       7       123       900   Impairment loss (1)     132       —       —       132   Total operating expenses     3,422       277       703       4,402   Income (loss) from operations     113       193       (703 )     (397 ) Other (expense) income     (14 )     —       39       25   Income (loss) before income taxes     99       193       (664 )     (372 ) Provision for income taxes     —       —       —       —   Net income (loss)   $ 99     $ 193     $ (664 )   $ (372 )     Predecessor       Three Months Ended March 31, 2023       Pharmacy Operations     Third-Party Administration     Corporate     Total Consolidated   Sales of products, net   $ 9,794     $ —     $ —     $ 9,794   Revenues from services     1,081       517       —       1,598   Revenues, net     10,875       517       —       11,392                                     Costs of products     8,196       —       —       8,196   Costs of services     —       49       —       49   Costs of revenue     8,196       49       —       8,245                                     Gross profit     2,679       468       —       3,147                                     Operating expenses:                                 Salaries and wages     1,445       33       120       1,598   Professional fees     383       96       295       774   Depreciation and amortization     60       4       —       64   Selling, general, and administrative     588       4       105       697   Total operating expenses     2,476       137       520       3,133   Income (loss) from operations     203       331       (520 )     14   Other expense     (13 )     —       (132 )     (144 ) Income (loss) before income taxes     190       331       (652 )     (130 ) Provision for income taxes     —       —       —       —   Net income (loss)   $ 190     $ 331     $ (652 )   $ (130 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Pharmacy Operations     Third-Party Administration     Corporate     Eliminations (1)     Total Consolidated   Total Assets as of March 31, 2024 (Successor)   $ 39,439     $ 4,733     $ —     $ (2,774 )   $ 41,398   Total Assets as of December 31, 2023 (Successor)   $ 38,516     $ 4,573     $ 69     $ (2,774 )   $ 40,384

Note 1 - Organization & Nature of Operations (Details Textual)		3 Months Ended
	Jul. 01, 2023 shares	Mar. 31, 2024	Oct. 21, 2010
Number of Reportable Segments		2
NextPlat Corp. and Messrs [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	632,269
Fernandez [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	211,470
Barreto [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	130,571
NextPlat, Chief Executive Officer, and Board Director [Member]
Ownership Percentage	53.00%
Pharmco LLC [Member]
Subsidiary, Ownership Percentage, Parent			100.00%

Note 3 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023
Cash, Uninsured Amount	$ 0.5
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member]
Number of Major Vendors	1	1
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | One Vendor [Member]
Concentration Risk, Percentage	98.00%	96.00%

Note 3 - Summary of Significant Accounting Policies - Trade, Net - Concentrations (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pharmacy Benefit Managers A [Member]
Concentration	33.00%	0.00%
Pharmacy Benefit Managers B [Member]
Concentration	21.00%	1.00%
Pharmacy Benefit Managers C [Member]
Concentration	16.00%	53.00%

Note 4 - Fair Value Measurements (Details Textual) - Common Stock Purchase Warrants [Member] $ / shares in Units, $ in Millions	Mar. 31, 2024 USD ($) $ / shares
Warrants and Rights Outstanding | $	$ 4.6
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.2
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.035
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	3
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.93
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.037
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.6
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.02

Note 5 - Revenue - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 14,628	$ 11,392
Prescription [Member]
Revenue	11,324	9,771
COVID-19 Testing [Member]
Revenue	0	45
Product [Member]
Revenue	11,324	9,816
Three Hundred Forty B Contract [Member]
Revenue	$ 3,304	$ 1,576

Note 6 - Earnings (Loss) Per Share - Components of Basic and Dilutes Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net loss attributable to common shareholders	$ (372)	$ (130)
Weighted average number of common shares outstanding during the period – basic and diluted (in shares)	6,240	3,356
Potentially dilutive common shares (in shares)	0	0
Diluted weighted average common shares outstanding (in shares)	6,240	3,356
Basic and diluted weighted average loss per common share (in dollars per share)	$ (0.06)	$ (0.04)
Diluted weighted average loss per common share (in dollars per share)	$ (0.06)	$ (0.04)
Antidilutive securities (in shares)	162,091	212,089
Warrant [Member]
Antidilutive securities (in shares)	102,468	60,152
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	59,623	151,937

Note 7 - Accounts Receivable - Trade, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 01, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 9,000
Accounts Receivable, after Allowance for Credit Loss		4,300,000	$ 3,400,000
Provision Approximation [Member]
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 9,000

Note 7 - Accounts Receivable - Trade, Net - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross accounts receivable – trade	$ 12,527	$ 8,611
Less: allowance for credit losses	(274)	(272)
Accounts receivable – trade, net	$ 12,253	$ 8,339

Note 8 - Receivables - Other, Net - Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Performance bonuses	$ 1,859	$ 1,602
Customers	179	192
Other	30	52
Other Receivables, Net, Current	$ 2,068	$ 1,846

Note 9 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Depreciation	$ 79,000	$ 44,000
Depreciation Approximation [Member]
Depreciation	$ 79,000	$ 44,000

Note 9 - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property and equipment, gross	$ 3,431	$ 3,420
Less: accumulated depreciation	(211)	(136)
Property and equipment, net	$ 3,220	3,284
Building [Member]
Property, Plant and Equipment, Useful Life (Year)	40 years
Property and equipment, gross	$ 2,116	2,116
Vehicles [Member]
Property and equipment, gross	$ 585	595
Vehicles [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Vehicles [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 388	388
Land [Member]
Property and equipment, gross	184	184
Leasehold Improvements [Member]
Property and equipment, gross	$ 119	76
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 39	39
Construction in Progress [Member]
Property and equipment, gross	$ 0	$ 22

Note 10 - Goodwill and Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Goodwill	$ 731,000		$ 731,000
Amortization of Intangible Assets	692,000	$ 12,000
Amortization Approximation [Member]
Amortization of Intangible Assets	700,000	$ 12,000
TPA Reporting Segment [Member]
Goodwill	$ 700,000		$ 700,000

Note 10 - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross intangible assets	$ 15,710	$ 15,710
Accumulated amortization	(2,004)	(1,312)
Net intangible assets	13,706	14,398
Pharmacy Records [Member]
Gross intangible assets	8,130	8,130
Accumulated amortization	(1,219)	(807)
Net intangible assets	6,911	7,323
Trade Names [Member]
Gross intangible assets	4,700	4,700
Accumulated amortization	(353)	(224)
Net intangible assets	4,347	4,476
Developed Technology Rights [Member]
Gross intangible assets	2,880	2,880
Accumulated amortization	(432)	(281)
Net intangible assets	$ 2,448	$ 2,599

Note 10 - Goodwill and Intangible Assets - Estimated Future Amortization of intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2024 (remaining nine months)	$ 2,004
2025	2,672
2026	2,672
2027	2,672
2028	1,571
Thereafter	2,115
Total	$ 13,706	$ 14,398

Note 11 - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts payable – trade	$ 12,752	$ 11,256
Accrued payroll and payroll taxes	356	167
Accrued PBM fees	366	571
Other accrued liabilities	81	164
Total	$ 13,555	$ 12,158

Note 12 - Notes Payable (Details Textual) - USD ($)		1 Months Ended					3 Months Ended
	Dec. 31, 2018	Sep. 30, 2022	Jul. 31, 2022	Sep. 30, 2021	Apr. 30, 2021	Jan. 31, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Notes Payable, Current							$ 144,000		$ 145,000
Property, Plant and Equipment, Net							3,220,000		3,284,000
Interest Expense, Debt							16,000	$ 51,000
Mortgage Note Payable Commercial Bank Collateralized [Member]
Secured Debt	$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Repayments of Debt						$ 11,901
Note Payable Collateralized Pharmacy Equipment [Member]
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Payments to Acquire Machinery and Equipment					$ 30,000
Debt Instrument, Periodic Payment				$ 331
Notes Payable, Current							5,000		6,000
Note Payable Collateralized [Member] | Pharmacy Equipment [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Payments to Acquire Machinery and Equipment			$ 90,000
Notes Payable, Current							70,000		74,000
Property, Plant and Equipment, Net							68,000		71,000
Note Payable Collateralized [Member] | Pharmacy Equipment [Member] | Sixty Monthly Payments [Member]
Debt Instrument, Periodic Payment			$ 1,859
Note Payable Collateralized [Member] | Vehicles [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Payments to Acquire Machinery and Equipment		$ 25,000
Debt Instrument, Periodic Payment		$ 1,143
Property, Plant and Equipment, Net							17,000		18,000
Notes Payable							$ 7,000		$ 10,000
Next Plat Investors [Member]
Debt Instrument, Maturity Date	Dec. 14, 2028

Note 12 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Note payable	$ 1,225	$ 1,255
Less: current portion of notes payable	144	145
Long-term portion of notes payable	1,081	1,110
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,118	1,140
Note Payable Uncollateralized [Member]
Note payable	25	25
Note Payable Collateralized [Member]
Note payable	$ 82	$ 90

Note 12 - Notes Payable - Schedule of Future Maturities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
2024 (remaining nine months)	$ 115
2025	114
2026	119
2027	124
2028	753
Total	$ 1,225

Note 13 - Stockholders' Equity (Details Textual) - USD ($)			1 Months Ended
	Jul. 01, 2023	May 05, 2023	Aug. 31, 2022	Aug. 30, 2022	Jul. 31, 2014	Mar. 31, 2024	Dec. 31, 2023	Sep. 02, 2022
Preferred Stock, Shares Authorized (in shares)						10,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001	$ 0.0001
Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debenture Purchase Agreement, Term (Year)		3 years
Debenture Purchase Agreement, Maximum Debt to be Issued		$ 10,000,000
Secured Debt		$ 0
Debt Conversion Agreement [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debt Conversion, Original Debt, Amount		$ 2,900,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)		1,312,379
Debt Conversion Agreement [Member] | NextPlat Corp. [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		570,599
Debt Conversion Agreement [Member] | Chairman and Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240
Debt Conversion Agreement [Member] | Vice-Chairman of the Board of Directors [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240
Amended and Restated Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount								$ 2,800,000
PIPE Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 1,000,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	230,056
Conversion Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 2,700,000					$ 600,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrants or Rights, Exercised (in shares)	230,000
Stock Issued During Period, Value, Warrants Exercised	$ 506,000
Stock Issued During Period, Shares, Cash Exercise of Warrants (in shares)	230,000
Conversion Warrants [Member] | NextPlat Corp. [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	172,213
Class of Warrants or Rights, Exercised, Cashless (in shares)	340,599
Conversion Warrants [Member] | Messrs. Fernandez and Barreto [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	115,402
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		5 years
Warrants and Rights Outstanding		$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		91,000
Inducement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 700,000				$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		330,000
Inducement Warrants [Member] | Chairman and Chief Executive Officer [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		190,000
Inducement Warrants [Member] | Vice-Chairman of the Board of Directors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		30,000
Inducement Warrants [Member] | Messrs. Fernandez [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	96,068
Inducement Warrants [Member] | Barreto [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	15,169
Securities Purchase Agreement [Member]
Proceeds From Issuance or Sale of Equity, Gross		$ 1,000,000
Equity Offering, Units Issued (in shares)		455,000
Equity Offering, Units Issued, Price Per Share (in dollars per share)		$ 2.2
Number of Shares Per Unit Issued (in shares)		1
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Number of Warrants Per Unit (in shares)		1
Proceeds from Issuance or Sale of Equity		$ 880,000
Payments of Stock Issuance Costs		70,000
Legal Fees		$ 50,000
Securities Purchase Agreement [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001
Sale of Stock, Number of Shares Issued in Transaction (in shares)				3,000
Proceeds from Issuance of Private Placement				$ 6,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)						51	51
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.001	$ 0.001
Stock Issued During Period, Shares, New Issues (in shares)			51		51
Preferred Stock, Voting Percentage					50.99%
Amount for Exchange of Voting Power					$ 20,000
Stock Issued During Period, Shares, Acquisitions (in shares)			127,564
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)						100,000	100,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001	$ 0.0001
Undesignated Preferred Stock, Shares Authorized (in shares)						9,899,949	9,899,949
Undesignated Preferred Stock, Par Value (in dollars per share)						$ 0.0001	$ 0.0001
Preferred Stock, Liquidation Preference Per Share (in dollars per share)				$ 2,000
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2,000
Preferred Stock Voting Rights Shares (in shares)				500
Debt Instrument, Convertible, Conversion Price (in dollars per share)				$ 4
Proceeds From Issuance or Sale of Equity, Gross				$ 1,000,000

Note 14 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expense	$ 65,000	$ 60,000
Share-Based Payment Arrangement, Expense, Tax Benefit	$ 0

Note 15 - Reportable Segments (Details Textual)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Number of Reportable Segments	2
Payments to Acquire Property, Plant, and Equipment	$ 24,000	$ 17,000
Pharmacy Operations [Member]
Payments to Acquire Property, Plant, and Equipment	$ 100,000	$ 17,000

Note 15 - Reportable Segments - Summary of Reportable Segments (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024		Mar. 31, 2023
Revenues, net		$ 14,628		$ 11,392
Costs of revenue		10,623		8,245
Gross profit		4,005		3,147
Salaries and wages		2,116		1,598
Professional fees		478		774
Depreciation and amortization		776		64
Selling, general, and administrative		900		697
Impairment loss		132	[1]	0
Total operating expenses		4,402		3,133
Income (loss) from operations		(397)		14
Other (expense) income		25		(144)
Income (loss) before income taxes		(372)		(130)
Provision for income taxes		0		0
Net loss		(372)		(130)
Intersegment Eliminations [Member]
Revenues, net		0		0
Costs of revenue		0		0
Gross profit		0		0
Salaries and wages		182		120
Professional fees		393		295
Depreciation and amortization		5		0
Selling, general, and administrative		123		105
Impairment loss	[1]	0
Total operating expenses		703		520
Income (loss) from operations		(703)		(520)
Other (expense) income		39		(132)
Income (loss) before income taxes		(664)		(652)
Provision for income taxes		0		0
Net loss		(664)		(652)
Product [Member]
Revenues, net		11,255		9,794
Costs of revenue		10,560		8,196
Product [Member] | Intersegment Eliminations [Member]
Revenues, net		0		0
Costs of revenue		0		0
Service [Member]
Revenues, net		3,373		1,598
Costs of revenue		63		49
Service [Member] | Intersegment Eliminations [Member]
Revenues, net		0		0
Costs of revenue		0		0
Pharmacy Operations [Member] | Operating Segments [Member]
Revenues, net		14,095		10,875
Costs of revenue		10,560		8,196
Gross profit		3,535		2,679
Salaries and wages		1,901		1,445
Professional fees		4		383
Depreciation and amortization		615		60
Selling, general, and administrative		770		588
Impairment loss	[1]	132
Total operating expenses		3,422		2,476
Income (loss) from operations		113		203
Other (expense) income		(14)		(13)
Income (loss) before income taxes		99		190
Provision for income taxes		0		0
Net loss		99		190
Pharmacy Operations [Member] | Product [Member] | Operating Segments [Member]
Revenues, net		11,255		9,794
Costs of revenue		10,560		8,196
Pharmacy Operations [Member] | Service [Member] | Operating Segments [Member]
Revenues, net		2,840		1,081
Costs of revenue		0		0
Third-party Administration [Member] | Operating Segments [Member]
Revenues, net		533		517
Costs of revenue		63		49
Gross profit		470		468
Salaries and wages		33		33
Professional fees		81		96
Depreciation and amortization		156		4
Selling, general, and administrative		7		4
Impairment loss	[1]	0
Total operating expenses		277		137
Income (loss) from operations		193		331
Other (expense) income		0		0
Income (loss) before income taxes		193		331
Provision for income taxes		0		0
Net loss		193		331
Third-party Administration [Member] | Product [Member] | Operating Segments [Member]
Revenues, net		0		0
Costs of revenue		0		0
Third-party Administration [Member] | Service [Member] | Operating Segments [Member]
Revenues, net		533		517
Costs of revenue		$ 63		$ 49
[1] Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Note 15 - Reportable Segments - Total Assets (Details) - USD ($) $ in Thousands		Mar. 31, 2024	Dec. 31, 2023
Total Assets		$ 41,398	$ 40,384
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Total Assets		0	69
Intersegment Eliminations [Member]
Total Assets	[1]	(2,774)	(2,774)
Pharmacy Operations [Member] | Operating Segments [Member]
Total Assets		39,439	38,516
Third-party Administration [Member] | Operating Segments [Member]
Total Assets		$ 4,733	$ 4,573
[1] Eliminations consist of investments in subsidiaries between the Pharmacy Operations segment and Corporate.

Note 16 - Related Party Transactions (Details Textual) - Management Services Agreement [Member] - NextPlat Corp. [Member] - USD ($)			3 Months Ended
	May 01, 2023	Feb. 01, 2023	Mar. 31, 2024	Mar. 31, 2023
Payment for Management Fee			$ 60,000
Management Fee Expense	$ 20,000	$ 25,000		$ 50,000

---